Materiały źródłowe

• #1 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  Gliomas are a diverse group of tumors originating from glial cells in the brain and spinal cord, representing the most common primary brain tumor within the central nervous system. In the United States, there are 6 cases of gliomas diagnosed per 100,000 individuals every year. […] Advances in molecular and genetic research have led to improved diagnostic accuracy and the development of targeted therapies. Despite these advancements, the diffuse and infiltrative nature of high-grade gliomas poses ongoing challenges in treatment and management. […] This activity reviews the pathophysiology, clinical presentations, and diagnostic techniques of glioma and provides the knowledge and skills to diagnose, treat, and manage patients with gliomas. […] Identify early signs and symptoms of gliomas, such as new-onset headaches, seizures, cognitive deficits, or focal neurological deficits, to facilitate timely diagnosis and intervention. […] Differentiate between various types of gliomas based on histopathological characteristics, molecular markers, and imaging findings to guide appropriate treatment strategies. […] Implement evidence-based treatment protocols tailored to the specific type and grade of glioma, incorporating the latest advances in medical research.

• #2 Glioma: What Is It, Causes, Symptoms, Treatment & Outlook

  https://my.clevelandclinic.org/health/diseases/21969-glioma

  Gliomas can affect children or adults. […] Most people with gliomas need a combination of treatments such as surgery, radiation therapy and chemotherapy. […] Gliomas are malignant (cancerous), but some can be very slow growing. […] Gliomas include: Astrocytomas, including glioblastomas and diffuse intrinsic pontine gliomas (DIPGs): These tumors start in cells called astrocytes. […] Gliomas are most common in older adults (over 65) and children (under 12). […] About 80,000 people are newly diagnosed with primary brain tumors each year in the U.S. Approximately 25% of these are gliomas. […] MRIs and CT scans are the most common imaging scans for brain tumors. […] If your healthcare provider sees an abnormal mass on your imaging scans, theyll do a biopsy. […] The biopsy will help them determine: If the tumor is cancerous.

• #3 Glioma: What Is It, Causes, Symptoms, Treatment & Outlook

  https://my.clevelandclinic.org/health/diseases/21969-glioma

  Gliomas can affect children or adults. […] Most people with gliomas need a combination of treatments such as surgery, radiation therapy and chemotherapy. […] Gliomas are malignant (cancerous), but some can be very slow growing. […] Gliomas include: Astrocytomas, including glioblastomas and diffuse intrinsic pontine gliomas (DIPGs): These tumors start in cells called astrocytes. […] Gliomas are most common in older adults (over 65) and children (under 12). […] About 80,000 people are newly diagnosed with primary brain tumors each year in the U.S. Approximately 25% of these are gliomas. […] MRIs and CT scans are the most common imaging scans for brain tumors. […] If your healthcare provider sees an abnormal mass on your imaging scans, theyll do a biopsy. […] The biopsy will help them determine: If the tumor is cancerous.

• #4 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Gliomas are primary central nervous system tumors that arise from glial progenitor cells. […] However, with recent advances in cancer genomics, molecular profiles have now been integrated into the classification and diagnosis of gliomas. […] In this review article, we discuss the clinical features, imaging findings, and molecular profiles of adult-type diffuse gliomas based on the new 2021 World Health Organization Classifications of Tumors of the central nervous system. […] Isocitrate dehydrogenase (IDH) mutation status is key to classify the adult-type diffuse gliomas. […] Molecular and genetic profiles have been integrated into the diagnosis of gliomas. […] Next-generation sequencing became essential for the diagnosis of gliomas. […] The 2021 WHO CNS classification separated adult-type diffuse gliomas from the pediatric type, and integrated the histopathological features of the tumors with the molecular profiles to provide a more concise diagnosis.

• #5 Diagnosing Glioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/natural-history/diagnosing

  If you have symptoms of glioma, your primary physician may refer you to a neurologist or neurosurgeon for further testing. This article will provide insight into the symptoms, exams, and tests used to diagnose gliomas. […] A thorough workup including dedicated imaging is necessary to diagnose a glioma in a timely fashion. […] Diagnosing glioma begins with the physician examining and interviewing the patient. After the provider recognizes potential symptoms of a brain tumor, they direct their patients for further testing. These tests often include computed tomography (CT or CAT) scans, magnetic resonance imaging (MRI), and possibly a biopsy. […] To diagnose a potential glioma, physicians will take a stepwise approach. […] Doctors often use the following methods in this order to diagnose glioma: Neurological exam, CT scan, MRI scan, Biopsy.

• #6 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  Tests and procedures used to diagnose glioma include: […] A neurological exam involves checking your vision, hearing, balance, coordination, strength and reflexes. If there’s difficulty with a certain task, it might be a clue that there could be a brain tumor. […] Imaging tests create pictures of your brain to look for signs of a brain tumor. MRI is the imaging test used most often. Sometimes you have an injection of dye in a vein before your MRI. This helps create better pictures. Other imaging tests may include CT and positron emission tomography, which is also called a PET scan. […] Sometimes a procedure called a biopsy is needed to remove some of the tissue for testing before treatment begins. It’s used when surgery isn’t an option for removing the brain tumor. If you will have surgery to remove your brain tumor, you might not need a biopsy before your surgery.

• #7 Glioma Diagnosis | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/glioma/glioma-diagnosis

  To make a glioma diagnosis, Memorial Sloan Kettering doctors take several steps, which may include: […] A neurological exam. This test of a persons vision, hearing, balance, coordination, strength, and reflexes can provide clues about which part of the brain is affected by a tumor. […] Imaging tests. CT, PET, and MRI scans can help doctors determine the location and size of a tumor. […] A tissue biopsy. A sample of tumor tissue can be taken before or during surgery. If before surgery, a small hole is drilled in the skull where the needle is inserted. This sample is then sent to a pathologist (a doctor who specializes in diagnosing disease) to determine the exact type of tumor. […] Genetic testing. A DNA sequencing test, such as MSK-IMPACT, may identify genetic mutations that drive a tumors growth. This may help determine the care plan our experts recommend.

• #8 Diagnosing Glioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/natural-history/diagnosing

  A physical exam alone will not diagnose glioma. However, health providers will use the physical exam to guide further diagnostic decisions. […] CT scans are a common first step in diagnosing a glioma. However, physicians often move on to another, more advanced scan, like an MRI. […] After looking at a CT scan, physicians may order an MRI to get a closer look at a potential glioma. […] Once your physician has found a tumor and you have been referred to a neurosurgeon, the neurosurgeon may decide to perform a biopsy to finalize the diagnosis before making a more definitive decision for removal of the tumor through a craniotomy. […] As some brain tumors can look alike on MRI, further testing such as a biopsy is needed for final accurate diagnosis. […] Depending on the glioma grade, physicians might perform more diagnostic tests to improve their treatment decisions. […] Diagnosing a glioma can be a journey. Physicians will combine physical examination results with advanced procedures like an MRI and biopsy to make a definitive diagnosis. […] Unfortunately, many gliomas are diagnosed in their higher grades as an early diagnosis is not possible.

• #9 Diagnosing Glioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/natural-history/diagnosing

  If you have symptoms of glioma, your primary physician may refer you to a neurologist or neurosurgeon for further testing. This article will provide insight into the symptoms, exams, and tests used to diagnose gliomas. […] A thorough workup including dedicated imaging is necessary to diagnose a glioma in a timely fashion. […] Diagnosing glioma begins with the physician examining and interviewing the patient. After the provider recognizes potential symptoms of a brain tumor, they direct their patients for further testing. These tests often include computed tomography (CT or CAT) scans, magnetic resonance imaging (MRI), and possibly a biopsy. […] To diagnose a potential glioma, physicians will take a stepwise approach. […] Doctors often use the following methods in this order to diagnose glioma: Neurological exam, CT scan, MRI scan, Biopsy.

• #10 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  Tests and procedures used to diagnose glioma include: […] A neurological exam involves checking your vision, hearing, balance, coordination, strength and reflexes. If there’s difficulty with a certain task, it might be a clue that there could be a brain tumor. […] Imaging tests create pictures of your brain to look for signs of a brain tumor. MRI is the imaging test used most often. Sometimes you have an injection of dye in a vein before your MRI. This helps create better pictures. Other imaging tests may include CT and positron emission tomography, which is also called a PET scan. […] Sometimes a procedure called a biopsy is needed to remove some of the tissue for testing before treatment begins. It’s used when surgery isn’t an option for removing the brain tumor. If you will have surgery to remove your brain tumor, you might not need a biopsy before your surgery.

• #11 Gliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/gliomas

  Gliomas are tumors that develop from glial cells, support cells found in the brain and spinal cord. […] Gliomas make up more than a quarter of all brain tumors. […] Diagnosing a glioma usually starts with a physical examination and a neurological examination to assess brain function. If a physician suspects a glioma or another type of brain tumor, a diagnostic imaging test such as magnetic resonance imaging (MRI) or computed tomography (CT) scan is most often the next step. […] MRI uses magnets, radio waves and advanced computer technology to image the brain and soft tissue structures like tumors. MRI is usually preferred to CT scan for glioma diagnosis. […] CT scan uses X-rays and a computer to image the skull bone, blood vessels and other structures in the brain. CT scan is a good option for patients who cannot undergo MRI, such as patients with pacemakers or other metallic implants.

• #12 Glioblastoma (Multiforme) Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/340870-overview

  Although a formal diagnosis of glioblastoma relies on histopathology and genetic markers for grading, structural MRIs are routinely performed and can be used to help guide surgery. […] After surgery, differentiating between recurrent tumor and scar tissue on the basis of MRI findings alone may be difficult. […] The National Comprehensive Cancer Network (NCCN) guidelines consider magnetic resonance imaging (MRI) of the brain to be the gold standard imaging study for glioblastoma. […] CT scan results offer a relatively high degree of confidence for the diagnosis of glioblastoma. […] MRI has a high degree of confidence in the diagnosis of glioblastoma and is widely used for identifying location and size of brain tumors. […] Positron emission tomography (PET) scanning is a useful adjunct to the evaluation of glioblastoma, particularly after resection. […] Angiographic findings associated with glioblastoma include the following: hypervascular mass with tumor blush; prominent feeding and draining vessels, as well as arteriovenous shunting (this may mimic an arteriovenous malformation).

• #13 Gliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/gliomas

  Gliomas are tumors that develop from glial cells, support cells found in the brain and spinal cord. […] Gliomas make up more than a quarter of all brain tumors. […] Diagnosing a glioma usually starts with a physical examination and a neurological examination to assess brain function. If a physician suspects a glioma or another type of brain tumor, a diagnostic imaging test such as magnetic resonance imaging (MRI) or computed tomography (CT) scan is most often the next step. […] MRI uses magnets, radio waves and advanced computer technology to image the brain and soft tissue structures like tumors. MRI is usually preferred to CT scan for glioma diagnosis. […] CT scan uses X-rays and a computer to image the skull bone, blood vessels and other structures in the brain. CT scan is a good option for patients who cannot undergo MRI, such as patients with pacemakers or other metallic implants.

• #14 Glioblastoma (Multiforme) Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/340870-overview

  Glioblastomas (malignant glioma) are the most common adult malignant brain tumors, and 20% of all primary brain neoplasms are glioblastoma tumors. […] The prognosis for this tumor is at the extreme worst end because of its high-grade status. […] In the fifth edition of the WHO classification of CNS tumors, glioblastomas are classified as a grade 4 diffuse astrocytic tumor in adults that must be IDH-wildtype. […] Computed tomography (CT) scanning can demonstrate the tumor and associated findings; however, in making the glioblastoma diagnosis, CT scanning may cause small tumors to be missed. […] Magnetic resonance imaging (MRI) is significantly more sensitive to the presence of tumor, as well as its associated findings, in the inclusion of peritumoral edema, and is the modality of choice for the examination of a patient with suspected or confirmed glioblastoma.

• #15 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  Tests and procedures used to diagnose glioma include: […] A neurological exam involves checking your vision, hearing, balance, coordination, strength and reflexes. If there’s difficulty with a certain task, it might be a clue that there could be a brain tumor. […] Imaging tests create pictures of your brain to look for signs of a brain tumor. MRI is the imaging test used most often. Sometimes you have an injection of dye in a vein before your MRI. This helps create better pictures. Other imaging tests may include CT and positron emission tomography, which is also called a PET scan. […] Sometimes a procedure called a biopsy is needed to remove some of the tissue for testing before treatment begins. It’s used when surgery isn’t an option for removing the brain tumor. If you will have surgery to remove your brain tumor, you might not need a biopsy before your surgery.

• #16 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  Imaging diagnostics are appropriate for evaluating suspected brain tumors and include the following: […] Magnetic resonance imaging (brain): This is the most sensitive study to determine the characteristics of brain tumors. Low-grade tumors usually do not enhance, while high-grade tumors have varying degrees of enhancement. […] The WHO classification of gliomas is used to guide treatment. As indicated in the classification, most patients will require surgical intervention via maximally safe resection or stereotactic-guided biopsy. […] Surgical resection is the mainstay of treatment with a goal of maximal safe resection, depending on tumor grading and location. […] Current acceptable practices include a maximal safe resection and the possibility of gross total resection, with radiographic follow-up. […] Maximal safe resection, concomitant chemoradiation, and radiographic follow-up for recurrence is an acceptable treatment.

• #17 Glioma | Neuro-Oncology Program | UPMC Hillman Cancer Center

  https://hillman.upmc.com/cancer-care/brain-nervous-system/brain-tumor/glioma

  Symptoms of glioma may vary based on where the tumor is. […] If a doctor suspects a brain tumor, they will order more advanced tests to confirm the diagnosis. […] MRI is the most common scan to diagnose brain cancer. Doctors can often diagnose the type of glioma based on how the tumor looks on the MRI. […] In a biopsy, doctors: Make a small hole in the skull. Use a thin needle to remove a tiny piece of the tumor. Analyze the sample using a microscope, genetic testing, or both, to plan the best treatment. […] Your care team at UPMC Hillman Cancer Center will choose the best treatment plan, based on: Your age. The type of glioma you have. Your test results. […] Doctors usually treat brain tumors with a mix of chemo and radiation. […] Sometimes, we can tell from an imaging test or biopsy that a glioma is low-grade and unlikely to grow or spread.

• #18 Glioblastoma Multiforme – AANS

  https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/

  Glioblastoma (GBM), also referred to as a grade IV astrocytoma, is a fast-growing and aggressive brain tumor. […] Sophisticated imaging techniques can accurately pinpoint the location of brain tumors. Diagnostic tools include computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI). […] Conventional MRI: Magnetic resonance imaging (MRI) is the most important imaging study for astrocytoma. […] MRI spectroscopy (MRS): This is an imaging tool, based on MRI, that provides information on the chemical composition of the tumor and works based on the fact that certain chemicals are abundant in the normal brain, while others are abundant in tumors (for example, choline). […] Functional MRI (fMRI): fMRI is a useful technique to find which parts of the brain become activated when the patient is asked to perform a certain task (for example, talking or moving one arm or leg).

• #19 Glioblastoma Multiforme – AANS

  https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/

  Glioblastoma (GBM), also referred to as a grade IV astrocytoma, is a fast-growing and aggressive brain tumor. […] Sophisticated imaging techniques can accurately pinpoint the location of brain tumors. Diagnostic tools include computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI). […] Conventional MRI: Magnetic resonance imaging (MRI) is the most important imaging study for astrocytoma. […] MRI spectroscopy (MRS): This is an imaging tool, based on MRI, that provides information on the chemical composition of the tumor and works based on the fact that certain chemicals are abundant in the normal brain, while others are abundant in tumors (for example, choline). […] Functional MRI (fMRI): fMRI is a useful technique to find which parts of the brain become activated when the patient is asked to perform a certain task (for example, talking or moving one arm or leg).

• #20 Diagnosing Glioma & Astrocytoma | NYU Langone Health

  https://nyulangone.org/conditions/glioma-astrocytoma/diagnosis

  A CT scan uses X-rays to create cross-sectional, three-dimensional images of the brain. […] Functional MRI, or fMRI, uses MRI imaging to measure the tiny metabolic changes that occur in an active part of the brain. […] In a perfusion MRI, a doctor can view the amount of blood flowing through different parts of the brain, as well as through a tumor. […] A PET scan detects tumor growth using a small amount of radioactive glucose, or sugar, which is injected into a vein. […] A stereotactic biopsy is a surgical procedure in which a doctor removes a small amount of brain tissue using a probe that is directed by a three-dimensional, computerized navigation system. […] Our neuropathologists perform precision molecular DNA testing, a sophisticated analysis of the DNA mutations in the tumor.

• #21 Glioblastoma (Risk Factors, Diagnosis & Treatments)

  https://www.cancertherapyadvisor.com/ddi/glioblastoma/

  Glioblastoma Diagnosis […] Clinicians need to perform a thorough diagnostic evaluation that combines noninvasive and invasive techniques to differentiate glioblastoma from lower-grade gliomas and brain cancers. […] Imaging tests are the most common noninvasive test for brain malignancies, including glioblastoma. […] An initial computed tomography (CT) scan can reveal an ill-defined tumor, prompting further testing. […] Standard CT scans are not sensitive enough to confirm a glioblastoma diagnosis, but they can be augmented with cerebral perfusion mapping. […] Magnetic resonance imaging (MRI) is often used in the evaluation of patients with suspected glioblastoma. […] A combination of diffusion-weighted imaging and MRI radiomics can facilitate an accurate diagnosis. […] Clinicians can perform surgical resection or a stereotactic biopsy to accurately assess tumor histology and molecular biomarker status. […] After resection or biopsy, molecular analysis of glioblastoma tumors can help establish the diagnosis and guide treatment.

• #22 Diagnosing Glioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/natural-history/diagnosing

  A physical exam alone will not diagnose glioma. However, health providers will use the physical exam to guide further diagnostic decisions. […] CT scans are a common first step in diagnosing a glioma. However, physicians often move on to another, more advanced scan, like an MRI. […] After looking at a CT scan, physicians may order an MRI to get a closer look at a potential glioma. […] Once your physician has found a tumor and you have been referred to a neurosurgeon, the neurosurgeon may decide to perform a biopsy to finalize the diagnosis before making a more definitive decision for removal of the tumor through a craniotomy. […] As some brain tumors can look alike on MRI, further testing such as a biopsy is needed for final accurate diagnosis. […] Depending on the glioma grade, physicians might perform more diagnostic tests to improve their treatment decisions. […] Diagnosing a glioma can be a journey. Physicians will combine physical examination results with advanced procedures like an MRI and biopsy to make a definitive diagnosis. […] Unfortunately, many gliomas are diagnosed in their higher grades as an early diagnosis is not possible.

• #23 Gliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/gliomas

  Gliomas are tumors that develop from glial cells, support cells found in the brain and spinal cord. […] Gliomas make up more than a quarter of all brain tumors. […] Diagnosing a glioma usually starts with a physical examination and a neurological examination to assess brain function. If a physician suspects a glioma or another type of brain tumor, a diagnostic imaging test such as magnetic resonance imaging (MRI) or computed tomography (CT) scan is most often the next step. […] MRI uses magnets, radio waves and advanced computer technology to image the brain and soft tissue structures like tumors. MRI is usually preferred to CT scan for glioma diagnosis. […] CT scan uses X-rays and a computer to image the skull bone, blood vessels and other structures in the brain. CT scan is a good option for patients who cannot undergo MRI, such as patients with pacemakers or other metallic implants.

• #24 Gliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/gliomas

  Gliomas are tumors that develop from glial cells, support cells found in the brain and spinal cord. […] Gliomas make up more than a quarter of all brain tumors. […] Diagnosing a glioma usually starts with a physical examination and a neurological examination to assess brain function. If a physician suspects a glioma or another type of brain tumor, a diagnostic imaging test such as magnetic resonance imaging (MRI) or computed tomography (CT) scan is most often the next step. […] MRI uses magnets, radio waves and advanced computer technology to image the brain and soft tissue structures like tumors. MRI is usually preferred to CT scan for glioma diagnosis. […] CT scan uses X-rays and a computer to image the skull bone, blood vessels and other structures in the brain. CT scan is a good option for patients who cannot undergo MRI, such as patients with pacemakers or other metallic implants.

• #25 Glioblastoma (Risk Factors, Diagnosis & Treatments)

  https://www.cancertherapyadvisor.com/ddi/glioblastoma/

  Glioblastoma Diagnosis […] Clinicians need to perform a thorough diagnostic evaluation that combines noninvasive and invasive techniques to differentiate glioblastoma from lower-grade gliomas and brain cancers. […] Imaging tests are the most common noninvasive test for brain malignancies, including glioblastoma. […] An initial computed tomography (CT) scan can reveal an ill-defined tumor, prompting further testing. […] Standard CT scans are not sensitive enough to confirm a glioblastoma diagnosis, but they can be augmented with cerebral perfusion mapping. […] Magnetic resonance imaging (MRI) is often used in the evaluation of patients with suspected glioblastoma. […] A combination of diffusion-weighted imaging and MRI radiomics can facilitate an accurate diagnosis. […] Clinicians can perform surgical resection or a stereotactic biopsy to accurately assess tumor histology and molecular biomarker status. […] After resection or biopsy, molecular analysis of glioblastoma tumors can help establish the diagnosis and guide treatment.

• #26 Diagnosing Glioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/natural-history/diagnosing

  A physical exam alone will not diagnose glioma. However, health providers will use the physical exam to guide further diagnostic decisions. […] CT scans are a common first step in diagnosing a glioma. However, physicians often move on to another, more advanced scan, like an MRI. […] After looking at a CT scan, physicians may order an MRI to get a closer look at a potential glioma. […] Once your physician has found a tumor and you have been referred to a neurosurgeon, the neurosurgeon may decide to perform a biopsy to finalize the diagnosis before making a more definitive decision for removal of the tumor through a craniotomy. […] As some brain tumors can look alike on MRI, further testing such as a biopsy is needed for final accurate diagnosis. […] Depending on the glioma grade, physicians might perform more diagnostic tests to improve their treatment decisions. […] Diagnosing a glioma can be a journey. Physicians will combine physical examination results with advanced procedures like an MRI and biopsy to make a definitive diagnosis. […] Unfortunately, many gliomas are diagnosed in their higher grades as an early diagnosis is not possible.

• #27 Glioblastoma (Multiforme) Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/340870-overview

  Although a formal diagnosis of glioblastoma relies on histopathology and genetic markers for grading, structural MRIs are routinely performed and can be used to help guide surgery. […] After surgery, differentiating between recurrent tumor and scar tissue on the basis of MRI findings alone may be difficult. […] The National Comprehensive Cancer Network (NCCN) guidelines consider magnetic resonance imaging (MRI) of the brain to be the gold standard imaging study for glioblastoma. […] CT scan results offer a relatively high degree of confidence for the diagnosis of glioblastoma. […] MRI has a high degree of confidence in the diagnosis of glioblastoma and is widely used for identifying location and size of brain tumors. […] Positron emission tomography (PET) scanning is a useful adjunct to the evaluation of glioblastoma, particularly after resection. […] Angiographic findings associated with glioblastoma include the following: hypervascular mass with tumor blush; prominent feeding and draining vessels, as well as arteriovenous shunting (this may mimic an arteriovenous malformation).

• #28 Diagnosing Glioma & Astrocytoma | NYU Langone Health

  https://nyulangone.org/conditions/glioma-astrocytoma/diagnosis

  A CT scan uses X-rays to create cross-sectional, three-dimensional images of the brain. […] Functional MRI, or fMRI, uses MRI imaging to measure the tiny metabolic changes that occur in an active part of the brain. […] In a perfusion MRI, a doctor can view the amount of blood flowing through different parts of the brain, as well as through a tumor. […] A PET scan detects tumor growth using a small amount of radioactive glucose, or sugar, which is injected into a vein. […] A stereotactic biopsy is a surgical procedure in which a doctor removes a small amount of brain tissue using a probe that is directed by a three-dimensional, computerized navigation system. […] Our neuropathologists perform precision molecular DNA testing, a sophisticated analysis of the DNA mutations in the tumor.

• #29 Glioblastoma Workup: Laboratory Studies, Imaging Studies, Other Tests

  https://emedicine.medscape.com/article/283252-workup

  Because glioblastoma is currently a molecular diagnosis, genetic studies for IDH and H3 status are essential, and genetic studies for TERT promoter mutation, EGFR gene amplification, and +7/-10 chromosome copy number changes are also important. Furthermore, excluding a metabolic or infectious process with routine laboratory studies is critical in the evaluation of an otherwise healthy patient who presents with new-onset seizures or neurologic deficit. […] Imaging studies of the brain are essential to make the diagnosis of glioblastoma (GBM). For complete discussion, see Imaging in Glioblastoma. […] Magnetic resonance imaging (MRI) with and without contrast is the study of choice for the evaluation and diagnosis of glioblastoma. […] Positron emission tomography (PET) is very sensitive at the initial stage of the diagnosis and can be helpful in diagnosing glioblastomas in difficult cases, such as those associated with radiation necrosis or hemorrhage.

• #30 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  Gliomas are highly complex and metabolically active brain tumors associated with poor prognosis. […] In this study, we performed metabolite analyses of blood samples collected from healthy controls and future glioma patients, up to eight years before glioma diagnosis, and on the day of glioma surgery. […] We discovered that metabolites related to early glioma development were associated with an increased energy turnover, as highlighted by elevated levels of TCA-related metabolites such as fumarate, malate, lactate and pyruvate in pre-diagnostic cases. […] High amino acid turnover in glioma tumor tissue is currently utilized for PET imaging, diagnosis and delineation of tumor margins. […] By examining blood-based metabolic progression patterns towards disease onset, we demonstrate that this high amino acid turnover is also detectable in a simple blood sample.

• #31 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  Gliomas are highly complex and metabolically active brain tumors associated with poor prognosis. […] In this study, we performed metabolite analyses of blood samples collected from healthy controls and future glioma patients, up to eight years before glioma diagnosis, and on the day of glioma surgery. […] We discovered that metabolites related to early glioma development were associated with an increased energy turnover, as highlighted by elevated levels of TCA-related metabolites such as fumarate, malate, lactate and pyruvate in pre-diagnostic cases. […] High amino acid turnover in glioma tumor tissue is currently utilized for PET imaging, diagnosis and delineation of tumor margins. […] By examining blood-based metabolic progression patterns towards disease onset, we demonstrate that this high amino acid turnover is also detectable in a simple blood sample.

• #32 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  Tests and procedures used to diagnose glioma include: […] A neurological exam involves checking your vision, hearing, balance, coordination, strength and reflexes. If there’s difficulty with a certain task, it might be a clue that there could be a brain tumor. […] Imaging tests create pictures of your brain to look for signs of a brain tumor. MRI is the imaging test used most often. Sometimes you have an injection of dye in a vein before your MRI. This helps create better pictures. Other imaging tests may include CT and positron emission tomography, which is also called a PET scan. […] Sometimes a procedure called a biopsy is needed to remove some of the tissue for testing before treatment begins. It’s used when surgery isn’t an option for removing the brain tumor. If you will have surgery to remove your brain tumor, you might not need a biopsy before your surgery.

• #33 Glioma: What Is It, Causes, Symptoms, Treatment & Outlook

  https://my.clevelandclinic.org/health/diseases/21969-glioma

  Gliomas can affect children or adults. […] Most people with gliomas need a combination of treatments such as surgery, radiation therapy and chemotherapy. […] Gliomas are malignant (cancerous), but some can be very slow growing. […] Gliomas include: Astrocytomas, including glioblastomas and diffuse intrinsic pontine gliomas (DIPGs): These tumors start in cells called astrocytes. […] Gliomas are most common in older adults (over 65) and children (under 12). […] About 80,000 people are newly diagnosed with primary brain tumors each year in the U.S. Approximately 25% of these are gliomas. […] MRIs and CT scans are the most common imaging scans for brain tumors. […] If your healthcare provider sees an abnormal mass on your imaging scans, theyll do a biopsy. […] The biopsy will help them determine: If the tumor is cancerous.

• #34 Gliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/gliomas

  A contrast agent (either swallowed as a pill or injected as a dye) can be used with each imaging test to increase the level of brain and tumor detail in the images. […] Depending on several factors, including glioma location, a biopsy may be appropriate. The biopsy procedure is conducted in one of two ways either open or stereotactic biopsy. Open biopsy is done while a neurosurgeon is performing brain tumor surgery to remove the tumor. Stereotactic biopsy does not require open surgery. Instead, a doctor performing stereotactic biopsy drills a small hole in the skull and then, using computer guidance, passes a needle through to obtain a tumor tissue sample.

• #35 Gliomas Diagnosis & Treatment – NYC | Columbia Neurosurgery in New York City

  https://www.neurosurgery.columbia.edu/patient-care/conditions/gliomas

  A contrast agent (either swallowed as a pill or injected as a dye) can be used with each imaging test to increase the level of brain and tumor detail in the images. […] Depending on several factors, including glioma location, a biopsy may be appropriate. The biopsy procedure is conducted in one of two ways either open or stereotactic biopsy. Open biopsy is done while a neurosurgeon is performing brain tumor surgery to remove the tumor. Stereotactic biopsy does not require open surgery. Instead, a doctor performing stereotactic biopsy drills a small hole in the skull and then, using computer guidance, passes a needle through to obtain a tumor tissue sample.

• #36 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  Tests and procedures used to diagnose glioma include: […] A neurological exam involves checking your vision, hearing, balance, coordination, strength and reflexes. If there’s difficulty with a certain task, it might be a clue that there could be a brain tumor. […] Imaging tests create pictures of your brain to look for signs of a brain tumor. MRI is the imaging test used most often. Sometimes you have an injection of dye in a vein before your MRI. This helps create better pictures. Other imaging tests may include CT and positron emission tomography, which is also called a PET scan. […] Sometimes a procedure called a biopsy is needed to remove some of the tissue for testing before treatment begins. It’s used when surgery isn’t an option for removing the brain tumor. If you will have surgery to remove your brain tumor, you might not need a biopsy before your surgery.

• #37 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  Tests and procedures used to diagnose glioma include: […] A neurological exam involves checking your vision, hearing, balance, coordination, strength and reflexes. If there’s difficulty with a certain task, it might be a clue that there could be a brain tumor. […] Imaging tests create pictures of your brain to look for signs of a brain tumor. MRI is the imaging test used most often. Sometimes you have an injection of dye in a vein before your MRI. This helps create better pictures. Other imaging tests may include CT and positron emission tomography, which is also called a PET scan. […] Sometimes a procedure called a biopsy is needed to remove some of the tissue for testing before treatment begins. It’s used when surgery isn’t an option for removing the brain tumor. If you will have surgery to remove your brain tumor, you might not need a biopsy before your surgery.

• #38 Diffuse Midline Glioma: Diagnosis and Treatment – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/tumors/diffuse-midline-gliomas

  To get an accurate diagnosis, a piece of tumor tissue will be removed during surgery, if possible. A neuropathologist should then review the tumor tissue. […] Diffuse midline gliomas are all grade 4 (also written as grade IV). This means they are malignant (cancerous) and fast-growing. […] In adults, a diffuse midline glioma diagnosis cant be made by imaging alone, because the tumors look similar to glioblastomas and other high-grade brain cancers. […] Because it can be hard to tell them apart, molecular testing is required. Some diffuse midline gliomas have changes in histone-related genes. The most common gene is h3K27M. A neuropathologist should confirm the diagnosis. […] The first treatment for diffuse midline glioma is surgery, if possible. The goal of surgery is to obtain tissue to determine the tumor type and remove as much tumor as possible without causing more symptoms. […] A team of experts including neuro-oncologists, neuroradiologists, radiation oncologists, and neurosurgeons should review the tumor to determine the best treatment plan.

• #39 Glioma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/glioma/diagnosis-treatment/drc-20350255

  A sample of the brain tumor may be sent to a lab for testing. The sample can come from a biopsy procedure. Or the sample can be taken during surgery to remove the glioma. […] Tests in the lab can determine if you have a glioma and what type you have. Other tests might show how quickly the glioma cells are growing. Advanced tests look at what DNA changes are present in the glioma cells. The test results help your health care team confirm your diagnosis and create a treatment plan.

• #40 Gliomas – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/intracranial-and-spinal-tumors/gliomas

  Diagnosis of gliomas is based primarily on MRI, including both standard T1- and T2-weighted imaging, preferably with gadolinium enhancement, followed by biopsy with histopathology and molecular profiling. […] Histopathology includes classical pathologic analysis of cellular morphology, immunohistochemical stains (eg, for IDH1/2 mutations), and in situ hybridization (eg, for EGFR mutations). […] Selected oncogene panels, targeted or whole-exome sequencing, RNA sequencing, and/or methylguanine-DNA methyl-transferase (MGMT) methylation analysis may be done. […] Methylation of the MGMT gene promoter is a prognostic factor in patients with glioblastoma multiforme; it predicts a good response to postoperative temozolamide and increased survival.

• #41 Glioma: Symptoms, Types, Diagnosis, and Treatment | Medanta

  https://www.medanta.org/patient-education-blog/glioma-symptoms-types-diagnosis-and-treatment

  The healthcare provider evaluates the symptoms and reviews an elaborate medical history first. Additionally, a thorough physical and neurological evaluation will be performed. The most popular imaging studies for brain tumors are MRIs and CT scans. Your healthcare provider looks for tumors in your brain as well as elsewhere in your body. An MRI and CT scan help determine the exact location and size of the lesion, which helps determine whether it can be surgically excised. […] If the healthcare provider observes an abnormal mass on the imaging scans, theyll advise or perform a biopsy. A biopsy is a procedure to analyze a sample of tissue to determine the type of glioma. […] The biopsy will help them determine: […] If the tumor is cancerous. […] Whether the tumor was brought on by an abnormal gene. […] The type of cells in the tumor. […] The grade (aggressiveness) of the tumor.

• #42 Glioma & Glioblastoma Symptoms, Diagnosis and Treatment | Pacific Brain Tumor Center

  https://www.pacificneuroscienceinstitute.org/brain-tumor/conditions/gliomas/

  A glioma is a type of tumor that originates in the glial cells, which are cells that provide support and protection for nerve cells in the brain and spinal cord. Gliomas are the most common type of primary brain tumor, accounting for approximately 30% of all brain tumors. […] Glioma, like other brain tumors, is currently best seen on magnetic resonance imaging (MRI) studies of the brain. Computerized tomography (CT) is also a good technique for seeing structures in the head and brain but does not show quite as much detail, as does MRI. […] A resection is needed to confirm the diagnosis of glioma and to grade the tumor, in order to guide the next steps of appropriate treatment and provide a prognosis for survival time. […] The microscopic structure of a glioma is extremely important in making decisions about treatment and in predicting survival. Based on features of cells within tumors, neuropathologists can often predict how aggressively a tumor will behave, and assign a WHO grade, which ultimately contributes to how long a patient will survive and what quality of life they may have.

• #43 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Gliomas are primary central nervous system tumors that arise from glial progenitor cells. […] However, with recent advances in cancer genomics, molecular profiles have now been integrated into the classification and diagnosis of gliomas. […] In this review article, we discuss the clinical features, imaging findings, and molecular profiles of adult-type diffuse gliomas based on the new 2021 World Health Organization Classifications of Tumors of the central nervous system. […] Isocitrate dehydrogenase (IDH) mutation status is key to classify the adult-type diffuse gliomas. […] Molecular and genetic profiles have been integrated into the diagnosis of gliomas. […] Next-generation sequencing became essential for the diagnosis of gliomas. […] The 2021 WHO CNS classification separated adult-type diffuse gliomas from the pediatric type, and integrated the histopathological features of the tumors with the molecular profiles to provide a more concise diagnosis.

• #44 Diagnostic Testing for Diffuse… | College of American Pathologists

  https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/diagnostic-testing-for-diffuse-gliomas

  The understanding of diffuse gliomas as discrete genetic and clinical entities has advanced markedly, and molecular testing and characterization have become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response. […] The evidence-based clinical practice guideline, Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas, informs an integrated diagnoses of pediatric and adult patients with diffusely infiltrative gliomas. […] Recommendation 1. IDH mutational testing must be performed on all diffuse gliomas. […] Recommendation 6. MGMT promoter methylation testing should be performed on all glioblastoma (GBM), IDH-wild type (WT). […] Recommendation 9. For histologic grade 2-3 DG that are IDH-WT, testing should be performed for whole chromosome 7 gain/whole chromosome 10 loss, EGFR amplification, and TERT promoter mutation to establish the molecular diagnosis of GBM, IDH-WT, grade 4.

• #45 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Adult-type diffuse gliomas are classified into: 1) astrocytoma, isocitrate dehydrogenase (IDH)-mutant (grade 2/3/4), 2) oligodendroglioma, IDH-mutant (grade 2/3) and 1p/19q-codeleted, and 3) glioblastoma, IDH-wildtype. […] IDH-wildtype glioma with high-grade features is diagnosed as glioblastoma, IDH-wildtype. […] When glioblastoma, IDH-wildtype is diagnosed, the presence of O-5-methylguanine-DNA methyltransferase (MGMT) promotor methylation should additionally be assessed, as it is associated with a better response to temozolomide and longer survival. […] Advances in cancer genomics and molecular testing methods have led to a new era of glioma diagnosis. […] The integration of molecular profiles into the diagnosis of gliomas has resulted in a clearer classification of these tumors.

• #46 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Gliomas are primary central nervous system tumors that arise from glial progenitor cells. […] However, with recent advances in cancer genomics, molecular profiles have now been integrated into the classification and diagnosis of gliomas. […] In this review article, we discuss the clinical features, imaging findings, and molecular profiles of adult-type diffuse gliomas based on the new 2021 World Health Organization Classifications of Tumors of the central nervous system. […] Isocitrate dehydrogenase (IDH) mutation status is key to classify the adult-type diffuse gliomas. […] Molecular and genetic profiles have been integrated into the diagnosis of gliomas. […] Next-generation sequencing became essential for the diagnosis of gliomas. […] The 2021 WHO CNS classification separated adult-type diffuse gliomas from the pediatric type, and integrated the histopathological features of the tumors with the molecular profiles to provide a more concise diagnosis.

• #47 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Adult-type diffuse gliomas are classified into: 1) astrocytoma, isocitrate dehydrogenase (IDH)-mutant (grade 2/3/4), 2) oligodendroglioma, IDH-mutant (grade 2/3) and 1p/19q-codeleted, and 3) glioblastoma, IDH-wildtype. […] IDH-wildtype glioma with high-grade features is diagnosed as glioblastoma, IDH-wildtype. […] When glioblastoma, IDH-wildtype is diagnosed, the presence of O-5-methylguanine-DNA methyltransferase (MGMT) promotor methylation should additionally be assessed, as it is associated with a better response to temozolomide and longer survival. […] Advances in cancer genomics and molecular testing methods have led to a new era of glioma diagnosis. […] The integration of molecular profiles into the diagnosis of gliomas has resulted in a clearer classification of these tumors.

• #48 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Adult-type diffuse gliomas are classified into: 1) astrocytoma, isocitrate dehydrogenase (IDH)-mutant (grade 2/3/4), 2) oligodendroglioma, IDH-mutant (grade 2/3) and 1p/19q-codeleted, and 3) glioblastoma, IDH-wildtype. […] IDH-wildtype glioma with high-grade features is diagnosed as glioblastoma, IDH-wildtype. […] When glioblastoma, IDH-wildtype is diagnosed, the presence of O-5-methylguanine-DNA methyltransferase (MGMT) promotor methylation should additionally be assessed, as it is associated with a better response to temozolomide and longer survival. […] Advances in cancer genomics and molecular testing methods have led to a new era of glioma diagnosis. […] The integration of molecular profiles into the diagnosis of gliomas has resulted in a clearer classification of these tumors.

• #49 Diagnostic Testing for Diffuse… | College of American Pathologists

  https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/diagnostic-testing-for-diffuse-gliomas

  The understanding of diffuse gliomas as discrete genetic and clinical entities has advanced markedly, and molecular testing and characterization have become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response. […] The evidence-based clinical practice guideline, Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas, informs an integrated diagnoses of pediatric and adult patients with diffusely infiltrative gliomas. […] Recommendation 1. IDH mutational testing must be performed on all diffuse gliomas. […] Recommendation 6. MGMT promoter methylation testing should be performed on all glioblastoma (GBM), IDH-wild type (WT). […] Recommendation 9. For histologic grade 2-3 DG that are IDH-WT, testing should be performed for whole chromosome 7 gain/whole chromosome 10 loss, EGFR amplification, and TERT promoter mutation to establish the molecular diagnosis of GBM, IDH-WT, grade 4.

• #50 Glioma | Brain tumours (primary) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/glioma-adults

  Your doctor looks to see if there are certain gene changes in the brain tumour cells. These tests are also called biomarker or molecular studies. Your doctor uses these test results to decide what type of glioma you have. […] IDH (isocitrate dehydrogenase) is a gene. Your doctor looks for permanent changes (mutations) in the IDH gene, which will help predict its behaviour. […] Your type of glioma will depend on whether there are changes in this gene: IDH mutant means you have changes (mutations) in the IDH gene; IDH wildtype means you dont have changes in the IDH gene (the term wildtype describes an unchanged gene).

• #51 Glioma vs. glioblastoma: What’s the difference? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/glioma-vs–glioblastoma–what-is-the-difference-in-these-brain-tumors-treatment-diagnosis.h00-159537378.html

  Certain genetic features can distinguish between different kinds of gliomas. Physicians test for IDH, an enzyme that affects metabolism in the cancer cells. Testing is also done for the genetic marker 1p19q, which helps distinguish oligodendroglioma and astrocytoma. […] After completing treatment for glioma, patients undergo regular MRIs to make sure their tumor has not recurred. How often a patient is seen varies, depending on their diagnosis and treatment plan. […] It’s important to make that distinction because these advances identify different prognoses and different optimal treatment options for patients.

• #52 Diagnostic Testing for Diffuse… | College of American Pathologists

  https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/diagnostic-testing-for-diffuse-gliomas

  The understanding of diffuse gliomas as discrete genetic and clinical entities has advanced markedly, and molecular testing and characterization have become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response. […] The evidence-based clinical practice guideline, Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas, informs an integrated diagnoses of pediatric and adult patients with diffusely infiltrative gliomas. […] Recommendation 1. IDH mutational testing must be performed on all diffuse gliomas. […] Recommendation 6. MGMT promoter methylation testing should be performed on all glioblastoma (GBM), IDH-wild type (WT). […] Recommendation 9. For histologic grade 2-3 DG that are IDH-WT, testing should be performed for whole chromosome 7 gain/whole chromosome 10 loss, EGFR amplification, and TERT promoter mutation to establish the molecular diagnosis of GBM, IDH-WT, grade 4.

• #53 Gliomas – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/intracranial-and-spinal-tumors/gliomas

  Diagnosis of gliomas is based primarily on MRI, including both standard T1- and T2-weighted imaging, preferably with gadolinium enhancement, followed by biopsy with histopathology and molecular profiling. […] Histopathology includes classical pathologic analysis of cellular morphology, immunohistochemical stains (eg, for IDH1/2 mutations), and in situ hybridization (eg, for EGFR mutations). […] Selected oncogene panels, targeted or whole-exome sequencing, RNA sequencing, and/or methylguanine-DNA methyl-transferase (MGMT) methylation analysis may be done. […] Methylation of the MGMT gene promoter is a prognostic factor in patients with glioblastoma multiforme; it predicts a good response to postoperative temozolamide and increased survival.

• #54 Glioblastoma (GBM) – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/glioblastoma-gbm/

  Molecular profiling is the detection of specific genes, proteins, or other molecules in a tumor. This information helps confirm tumor diagnosis, inform treatment options, and predict prognosis. […] The 2021 World Health Organization (WHO) update on CNS tumor classifications defined glioblastomas as IDH-wild type. […] Glioblastomas are characterized by EGFR amplification, TERT promoter mutation, or combined gain of chromosome 7/loss of chromosome 10 copy number changes. […] Tumors that exhibit MGMT promoter hypermethylation have been found to predict a longer length of survival and tend to respond better to chemotherapy like temozolomide (Temodar).

• #55 Glioblastoma (GBM) – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/glioblastoma-gbm/

  Molecular profiling is the detection of specific genes, proteins, or other molecules in a tumor. This information helps confirm tumor diagnosis, inform treatment options, and predict prognosis. […] The 2021 World Health Organization (WHO) update on CNS tumor classifications defined glioblastomas as IDH-wild type. […] Glioblastomas are characterized by EGFR amplification, TERT promoter mutation, or combined gain of chromosome 7/loss of chromosome 10 copy number changes. […] Tumors that exhibit MGMT promoter hypermethylation have been found to predict a longer length of survival and tend to respond better to chemotherapy like temozolomide (Temodar).

• #56 Glioblastoma (GBM) – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/glioblastoma-gbm/

  Molecular profiling is the detection of specific genes, proteins, or other molecules in a tumor. This information helps confirm tumor diagnosis, inform treatment options, and predict prognosis. […] The 2021 World Health Organization (WHO) update on CNS tumor classifications defined glioblastomas as IDH-wild type. […] Glioblastomas are characterized by EGFR amplification, TERT promoter mutation, or combined gain of chromosome 7/loss of chromosome 10 copy number changes. […] Tumors that exhibit MGMT promoter hypermethylation have been found to predict a longer length of survival and tend to respond better to chemotherapy like temozolomide (Temodar).

• #57 Diagnostic Testing for Diffuse… | College of American Pathologists

  https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/diagnostic-testing-for-diffuse-gliomas

  The understanding of diffuse gliomas as discrete genetic and clinical entities has advanced markedly, and molecular testing and characterization have become an established component of the integrated diagnosis of these tumors, allowing for a more refined definition of disease and better prediction of both prognosis and therapeutic response. […] The evidence-based clinical practice guideline, Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas, informs an integrated diagnoses of pediatric and adult patients with diffusely infiltrative gliomas. […] Recommendation 1. IDH mutational testing must be performed on all diffuse gliomas. […] Recommendation 6. MGMT promoter methylation testing should be performed on all glioblastoma (GBM), IDH-wild type (WT). […] Recommendation 9. For histologic grade 2-3 DG that are IDH-WT, testing should be performed for whole chromosome 7 gain/whole chromosome 10 loss, EGFR amplification, and TERT promoter mutation to establish the molecular diagnosis of GBM, IDH-WT, grade 4.

• #58 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This may suggest that cfDNA could serve as a useful biomarker for differentiating GB patients from healthy individuals and serve as an indicator for tumor progression. […] cfDNA may also help in the quantitative measurement of genetic (e.g., IDH mutations) or epigenetic (MGMT methylation) alterations. […] In addition, quantitative polymerase chain reaction (qPCR) analysis has revealed a notably elevated number of LINE-1 ORF2 copies in multiple regions of healthy adult human brain samples, indicating the presence of LINE-1 activity within the brain. […] The utilization of retrotransposon capture sequencing (RC-Seq) also allowed the authors to identify somatic LINE-1 insertions in protein-coding genes that were differentially expressed and actively functioning within the brain. […] The study of Husain et al. examined pre-radiotherapy cfDNA levels using next-generation sequencing (NGS) and compared the results to immunohistochemical (IHC) analysis, showing a high degree of accordance.

• #59 Glioma Diagnosis | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/glioma/glioma-diagnosis

  To make a glioma diagnosis, Memorial Sloan Kettering doctors take several steps, which may include: […] A neurological exam. This test of a persons vision, hearing, balance, coordination, strength, and reflexes can provide clues about which part of the brain is affected by a tumor. […] Imaging tests. CT, PET, and MRI scans can help doctors determine the location and size of a tumor. […] A tissue biopsy. A sample of tumor tissue can be taken before or during surgery. If before surgery, a small hole is drilled in the skull where the needle is inserted. This sample is then sent to a pathologist (a doctor who specializes in diagnosing disease) to determine the exact type of tumor. […] Genetic testing. A DNA sequencing test, such as MSK-IMPACT, may identify genetic mutations that drive a tumors growth. This may help determine the care plan our experts recommend.

• #60 Gliomas – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/intracranial-and-spinal-tumors/gliomas

  Diagnosis of gliomas is based primarily on MRI, including both standard T1- and T2-weighted imaging, preferably with gadolinium enhancement, followed by biopsy with histopathology and molecular profiling. […] Histopathology includes classical pathologic analysis of cellular morphology, immunohistochemical stains (eg, for IDH1/2 mutations), and in situ hybridization (eg, for EGFR mutations). […] Selected oncogene panels, targeted or whole-exome sequencing, RNA sequencing, and/or methylguanine-DNA methyl-transferase (MGMT) methylation analysis may be done. […] Methylation of the MGMT gene promoter is a prognostic factor in patients with glioblastoma multiforme; it predicts a good response to postoperative temozolamide and increased survival.

• #61 Gliomas – Neurologic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/neurologic-disorders/intracranial-and-spinal-tumors/gliomas

  Diagnosis of gliomas is based primarily on MRI, including both standard T1- and T2-weighted imaging, preferably with gadolinium enhancement, followed by biopsy with histopathology and molecular profiling. […] Histopathology includes classical pathologic analysis of cellular morphology, immunohistochemical stains (eg, for IDH1/2 mutations), and in situ hybridization (eg, for EGFR mutations). […] Selected oncogene panels, targeted or whole-exome sequencing, RNA sequencing, and/or methylguanine-DNA methyl-transferase (MGMT) methylation analysis may be done. […] Methylation of the MGMT gene promoter is a prognostic factor in patients with glioblastoma multiforme; it predicts a good response to postoperative temozolamide and increased survival.

• #62 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Adult-type diffuse gliomas are classified into: 1) astrocytoma, isocitrate dehydrogenase (IDH)-mutant (grade 2/3/4), 2) oligodendroglioma, IDH-mutant (grade 2/3) and 1p/19q-codeleted, and 3) glioblastoma, IDH-wildtype. […] IDH-wildtype glioma with high-grade features is diagnosed as glioblastoma, IDH-wildtype. […] When glioblastoma, IDH-wildtype is diagnosed, the presence of O-5-methylguanine-DNA methyltransferase (MGMT) promotor methylation should additionally be assessed, as it is associated with a better response to temozolomide and longer survival. […] Advances in cancer genomics and molecular testing methods have led to a new era of glioma diagnosis. […] The integration of molecular profiles into the diagnosis of gliomas has resulted in a clearer classification of these tumors.

• #63 Classification and Diagnosis of Adult Glioma: A Scoping Review

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9833487/

  Adult-type diffuse gliomas are classified into: 1) astrocytoma, isocitrate dehydrogenase (IDH)-mutant (grade 2/3/4), 2) oligodendroglioma, IDH-mutant (grade 2/3) and 1p/19q-codeleted, and 3) glioblastoma, IDH-wildtype. […] IDH-wildtype glioma with high-grade features is diagnosed as glioblastoma, IDH-wildtype. […] When glioblastoma, IDH-wildtype is diagnosed, the presence of O-5-methylguanine-DNA methyltransferase (MGMT) promotor methylation should additionally be assessed, as it is associated with a better response to temozolomide and longer survival. […] Advances in cancer genomics and molecular testing methods have led to a new era of glioma diagnosis. […] The integration of molecular profiles into the diagnosis of gliomas has resulted in a clearer classification of these tumors.

• #64 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  Gliomas comprise the most frequent primary central nervous system (CNS) tumors, characterized by remarkable genetic and epigenetic heterogeneity, difficulty in monitoring, and increased relapse and mortality rates. […] Tissue biopsy is an established method of tumor cell collection and analysis that enables diagnosis, classification of different tumor types, and prediction of prognosis upon confirmation of tumor’s location for surgical removal. […] However, it is an invasive and often challenging procedure that cannot be used for frequent patient screening, detection of mutations, disease monitoring, or resistance to therapy. […] To this end, the minimally invasive procedure of liquid biopsy has emerged, allowing effortless tumor sampling and enabling continuous monitoring. […] It is considered a novel preferable way to obtain faster data on potential tumor risk, personalized diagnosis, prognosis, and recurrence evaluation.

• #65 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  Gliomas comprise the most frequent primary central nervous system (CNS) tumors, characterized by remarkable genetic and epigenetic heterogeneity, difficulty in monitoring, and increased relapse and mortality rates. […] Tissue biopsy is an established method of tumor cell collection and analysis that enables diagnosis, classification of different tumor types, and prediction of prognosis upon confirmation of tumor’s location for surgical removal. […] However, it is an invasive and often challenging procedure that cannot be used for frequent patient screening, detection of mutations, disease monitoring, or resistance to therapy. […] To this end, the minimally invasive procedure of liquid biopsy has emerged, allowing effortless tumor sampling and enabling continuous monitoring. […] It is considered a novel preferable way to obtain faster data on potential tumor risk, personalized diagnosis, prognosis, and recurrence evaluation.

• #66 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  Gliomas comprise the most frequent primary central nervous system (CNS) tumors, characterized by remarkable genetic and epigenetic heterogeneity, difficulty in monitoring, and increased relapse and mortality rates. […] Tissue biopsy is an established method of tumor cell collection and analysis that enables diagnosis, classification of different tumor types, and prediction of prognosis upon confirmation of tumor’s location for surgical removal. […] However, it is an invasive and often challenging procedure that cannot be used for frequent patient screening, detection of mutations, disease monitoring, or resistance to therapy. […] To this end, the minimally invasive procedure of liquid biopsy has emerged, allowing effortless tumor sampling and enabling continuous monitoring. […] It is considered a novel preferable way to obtain faster data on potential tumor risk, personalized diagnosis, prognosis, and recurrence evaluation.

• #67 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This technique provides vital diagnostic and prognostic information, as well as real-time updates on tumor status. […] In the case of gliomas, the use of a liquid biopsy is extremely promising. […] LB has allowed the detection of cfDNA in cancer patients, as mentioned above, which has created the potential of its incorporation into clinical practice, with the goal of identifying both genetic and epigenetic alterations in tumors. […] cfDNA may be a suitable molecular marker, indicative of tumor status, which will enable disease monitoring and distinction between tumor-free individuals and brain tumor patients. […] One study demonstrated that the serum of control subjects was consistently characterized by low levels of cfDNA, in contrast to GB patients who had higher cfDNA concentrations.

• #68 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This technique provides vital diagnostic and prognostic information, as well as real-time updates on tumor status. […] In the case of gliomas, the use of a liquid biopsy is extremely promising. […] LB has allowed the detection of cfDNA in cancer patients, as mentioned above, which has created the potential of its incorporation into clinical practice, with the goal of identifying both genetic and epigenetic alterations in tumors. […] cfDNA may be a suitable molecular marker, indicative of tumor status, which will enable disease monitoring and distinction between tumor-free individuals and brain tumor patients. […] One study demonstrated that the serum of control subjects was consistently characterized by low levels of cfDNA, in contrast to GB patients who had higher cfDNA concentrations.

• #69 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This may suggest that cfDNA could serve as a useful biomarker for differentiating GB patients from healthy individuals and serve as an indicator for tumor progression. […] cfDNA may also help in the quantitative measurement of genetic (e.g., IDH mutations) or epigenetic (MGMT methylation) alterations. […] In addition, quantitative polymerase chain reaction (qPCR) analysis has revealed a notably elevated number of LINE-1 ORF2 copies in multiple regions of healthy adult human brain samples, indicating the presence of LINE-1 activity within the brain. […] The utilization of retrotransposon capture sequencing (RC-Seq) also allowed the authors to identify somatic LINE-1 insertions in protein-coding genes that were differentially expressed and actively functioning within the brain. […] The study of Husain et al. examined pre-radiotherapy cfDNA levels using next-generation sequencing (NGS) and compared the results to immunohistochemical (IHC) analysis, showing a high degree of accordance.

• #70 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This may suggest that cfDNA could serve as a useful biomarker for differentiating GB patients from healthy individuals and serve as an indicator for tumor progression. […] cfDNA may also help in the quantitative measurement of genetic (e.g., IDH mutations) or epigenetic (MGMT methylation) alterations. […] In addition, quantitative polymerase chain reaction (qPCR) analysis has revealed a notably elevated number of LINE-1 ORF2 copies in multiple regions of healthy adult human brain samples, indicating the presence of LINE-1 activity within the brain. […] The utilization of retrotransposon capture sequencing (RC-Seq) also allowed the authors to identify somatic LINE-1 insertions in protein-coding genes that were differentially expressed and actively functioning within the brain. […] The study of Husain et al. examined pre-radiotherapy cfDNA levels using next-generation sequencing (NGS) and compared the results to immunohistochemical (IHC) analysis, showing a high degree of accordance.

• #71 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This may suggest that cfDNA could serve as a useful biomarker for differentiating GB patients from healthy individuals and serve as an indicator for tumor progression. […] cfDNA may also help in the quantitative measurement of genetic (e.g., IDH mutations) or epigenetic (MGMT methylation) alterations. […] In addition, quantitative polymerase chain reaction (qPCR) analysis has revealed a notably elevated number of LINE-1 ORF2 copies in multiple regions of healthy adult human brain samples, indicating the presence of LINE-1 activity within the brain. […] The utilization of retrotransposon capture sequencing (RC-Seq) also allowed the authors to identify somatic LINE-1 insertions in protein-coding genes that were differentially expressed and actively functioning within the brain. […] The study of Husain et al. examined pre-radiotherapy cfDNA levels using next-generation sequencing (NGS) and compared the results to immunohistochemical (IHC) analysis, showing a high degree of accordance.

• #72 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This approach may prove beneficial in cases where surgery is not possible or in cases of adult diffuse glioma recurrence. […] Finally, in the study of Palande et al., gene mutations and gene–gene fusions were detected in the circulating cfDNA of patients with GB. […] This study utilized the ChiTaRS 5.0 gene–gene fusion database to identify gene–gene fusions in cfDNA and tumor DNA samples. […] Notably, fusions involving PDGFRA were found in 44% of GB samples, which can be effectively targeted using tyrosine kinase inhibitors. […] The combination of liquid biopsy and radiomics/radiogenomics can offer a promising avenue for non-invasive disease diagnosis and provide valuable insights for treatment planning. […] The extension of this approach to gliomas represents a significant opportunity to improve the accuracy and efficiency of non-invasive diagnosis and monitoring.

• #73 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  Metabolic changes associated with glioma include elevated levels of certain metabolites related to an increased energy turnover. […] To fully understand changes in metabolite levels during the timeline of glioma development and progression, it would be necessary to analyze both pre-diagnostic samples and surgical samples over time from the same individuals. […] In this study, we examined blood plasma samples collected years before diagnosis, as well as on the day of surgery. […] We compared pre-diagnostic plasma samples with matched healthy controls to find early metabolic markers related to glioma development. […] We also analyzed surgery samples in relation to pre-diagnostic samples, from the same individuals, to find metabolites related to glioma progression. […] To find metabolites that could indicate early glioma development, we analyzed plasma samples from patients that had been collected up to eight years before glioma diagnosis, and carefully matched plasma samples from cancer free healthy controls.

• #74 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  Gliomas are highly complex and metabolically active brain tumors associated with poor prognosis. […] In this study, we performed metabolite analyses of blood samples collected from healthy controls and future glioma patients, up to eight years before glioma diagnosis, and on the day of glioma surgery. […] We discovered that metabolites related to early glioma development were associated with an increased energy turnover, as highlighted by elevated levels of TCA-related metabolites such as fumarate, malate, lactate and pyruvate in pre-diagnostic cases. […] High amino acid turnover in glioma tumor tissue is currently utilized for PET imaging, diagnosis and delineation of tumor margins. […] By examining blood-based metabolic progression patterns towards disease onset, we demonstrate that this high amino acid turnover is also detectable in a simple blood sample.

• #75 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  It was notable that many of the metabolites that were higher at surgery were either amino acids or metabolites of amino acid metabolism. […] The same progression pattern with elevated levels towards surgery from already elevated levels years before diagnosis was also seen for pyruvate, lactate, urea and 2,3-dihydroxybutanoate. […] This study confirms and validates previous findings in a new patient dataset. […] The main points of novelty are the identification of early metabolic markers that indicate glioma development, years before diagnosis, and metabolites related to the progression of glioma up to the time of surgery, in the same individuals.

• #76 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #77 Blood Test Potentially Improves Glioma Diagnosis and Monitoring

  https://www.genengnews.com/topics/cancer/blood-test-potentially-improves-glioma-diagnosis-and-monitoring/

  Researchers at Massachusetts General Hospital (MGH) developed an enhanced form of liquid biopsy that can detect and monitor genetic mutations that promote the growth of the most common type of adult brain tumors in blood samples. […] By comparing blood samples from patients with gliomas with tumor biopsy tissues from the same patients, the researchers in the department of neurosurgery at MGH found that a novel digital droplet polymerase chain reaction (ddPCR) blood test they pioneered could accurately detect and monitor two mutations of the gene TERT, C228T, and C250T, over time. […] Their discovery, “TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas,” was published in the journal Clinical Cancer Research. […] “Liquid biopsy offers a minimally invasive tool to diagnose and monitor the heterogeneous molecular landscape of tumors over time and therapy,” noted the researchers.

• #78 Blood Test Potentially Improves Glioma Diagnosis and Monitoring

  https://www.genengnews.com/topics/cancer/blood-test-potentially-improves-glioma-diagnosis-and-monitoring/

  Researchers at Massachusetts General Hospital (MGH) developed an enhanced form of liquid biopsy that can detect and monitor genetic mutations that promote the growth of the most common type of adult brain tumors in blood samples. […] By comparing blood samples from patients with gliomas with tumor biopsy tissues from the same patients, the researchers in the department of neurosurgery at MGH found that a novel digital droplet polymerase chain reaction (ddPCR) blood test they pioneered could accurately detect and monitor two mutations of the gene TERT, C228T, and C250T, over time. […] Their discovery, “TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas,” was published in the journal Clinical Cancer Research. […] “Liquid biopsy offers a minimally invasive tool to diagnose and monitor the heterogeneous molecular landscape of tumors over time and therapy,” noted the researchers.

• #79 Blood Test Potentially Improves Glioma Diagnosis and Monitoring

  https://www.genengnews.com/topics/cancer/blood-test-potentially-improves-glioma-diagnosis-and-monitoring/

  Telomerase reverse transcriptase (TERT) has received a great deal of attention in recent years for its role as a prognostic and predictive molecular marker of glioma. […] “By ‘supercharging’ our ddPCR assay with novel technical improvements, we showed for the first time that the most prevalent mutation in malignant gliomas can be detected in blood, opening a new landscape for detection and monitoring of the tumors,” she added. […] The ddPCR assay has the ability to detect the presence of a glioma by 62.5%, which is an improvement over previous assays for TERT mutations in the blood for brain tumors, compared to the standard of tissue-based detection of TERT mutations. […] “We envision the future integration of tests like this one into the clinical care of our patients with brain tumors,” said Bob S. Carter, MD, chief of neurosurgery and co-director of the MGH Brain Tumor Center. […] The researchers look forward to expanding their assay to be able to differentiate many types of brain tumors. Their discovery has the potential to improve the diagnosis and monitoring of gliomas and may lead to future advancements in brain tumor diagnosis.

• #80 New Blood Test Enables Minimally Invasive Glioma Diagnosis | Clinical Lab Products

  https://clpmag.com/diagnostic-technologies/molecular-diagnostics/new-blood-test-enables-minimally-invasive-glioma-diagnosis/

  New Blood Test Enables Minimally Invasive Glioma Diagnosis […] Researchers have developed a novel blood test that allows for the minimally invasive detection and monitoring of IDH1 mutant gliomas, offering an alternative to traditional biopsy methods. […] The mt-IDHIdx blood test detects IDH1 mutations in gliomas using just 2ml of blood, reducing the need for invasive tissue biopsies. […] Validation of the test across a study population demonstrated a sensitivity of 75.0% and specificity of 88.7%, providing reliable diagnostic accuracy compared to the traditional tissue-based gold standard. […] Currently, neuroimaging followed by tissue biopsy testing (surgical biopsy and/or resection) is the gold standard for diagnosing IDHI mutant gliomas. […] Now researchers from Massachusetts General Hospital detailed a new blood-based test, mt-IDHIdx, that allows for the minimally invasive detection of tumor-derived extracellular RNA using only 2ml of blood.

• #81 New Blood Test Enables Minimally Invasive Glioma Diagnosis | Clinical Lab Products

  https://clpmag.com/diagnostic-technologies/molecular-diagnostics/new-blood-test-enables-minimally-invasive-glioma-diagnosis/

  Results from our plasma testing demonstrate an overall sensitivity of 75.0%, specificity 88.7%, positive predictive value 90.9%, and negative predictive value 70.1% compared to the tissue gold standard. […] Detection of the IDH1 mutation in blood means that these tumors can be diagnosed without a biopsy, and can be monitored overtime to track disease progression, response to treatment or recurrence using a simple blood sample. […] Importantly, the FDA recently approved a drug (vorasidenib) for this mutation in glioma this means that the test, once approved, can be used to stratify these patients for this treatment and can monitor disease course.

• #82 New Blood Test Enables Minimally Invasive Glioma Diagnosis | Clinical Lab Products

  https://clpmag.com/diagnostic-technologies/molecular-diagnostics/new-blood-test-enables-minimally-invasive-glioma-diagnosis/

  Results from our plasma testing demonstrate an overall sensitivity of 75.0%, specificity 88.7%, positive predictive value 90.9%, and negative predictive value 70.1% compared to the tissue gold standard. […] Detection of the IDH1 mutation in blood means that these tumors can be diagnosed without a biopsy, and can be monitored overtime to track disease progression, response to treatment or recurrence using a simple blood sample. […] Importantly, the FDA recently approved a drug (vorasidenib) for this mutation in glioma this means that the test, once approved, can be used to stratify these patients for this treatment and can monitor disease course.

• #83 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  When evaluating a patient with a suspected glioma, it is crucial to consider a range of differential diagnoses to ensure accurate diagnosis and appropriate treatment. […] Several techniques have been used to increase the extent of resection of gliomas, including intraoperative MRI and fluorescein-guided resections. […] Postoperative radiation therapy aims to eliminate residual tumor cells, reduce recurrence risk, and prolong survival. […] The prognosis of patients with gliomas depends on several factors, as follows: Age of the patient, Comorbidities, Grade and location of the tumor, Presence of hydrocephalus, Response to adjuvant therapy, Extent of surgical resection. […] Patients with gliomas benefit from consultations with a multidisciplinary team of specialists to ensure comprehensive and personalized care. […] Deterrence and patient education are crucial components in managing gliomas, aiming to improve patient outcomes and quality of life.

• #84 Glioma Diagnosis and Classification: Illuminating the Gold Standard | SpringerLink

  https://link.springer.com/chapter/10.1007/978-3-030-72084-1_1

  Accurate glioma classification is essential for optimal patient care, and requires integration of histological and immunohistochemical findings with molecular features, in the context of imaging and demographic information. […] This paper will introduce classic histologic features of gliomas in contrast to nonneoplastic brain parenchyma, describe the basic clinical algorithm used to classify infiltrating gliomas, and demonstrate how the classification is reflected in the diagnostic reporting structure. […] Key molecular features include IDH mutational status and 1p/19q codeletion. […] In addition, molecular changes may indicate poor prognosis despite lower grade histology, such as findings consistent with two grade IV infiltrating gliomas: molecular glioblastoma and diffuse midline gliomas. […] Detailed molecular characterization aids in optimization of treatment with the goal of improved patient outcomes.

• #85 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This approach may prove beneficial in cases where surgery is not possible or in cases of adult diffuse glioma recurrence. […] Finally, in the study of Palande et al., gene mutations and gene–gene fusions were detected in the circulating cfDNA of patients with GB. […] This study utilized the ChiTaRS 5.0 gene–gene fusion database to identify gene–gene fusions in cfDNA and tumor DNA samples. […] Notably, fusions involving PDGFRA were found in 44% of GB samples, which can be effectively targeted using tyrosine kinase inhibitors. […] The combination of liquid biopsy and radiomics/radiogenomics can offer a promising avenue for non-invasive disease diagnosis and provide valuable insights for treatment planning. […] The extension of this approach to gliomas represents a significant opportunity to improve the accuracy and efficiency of non-invasive diagnosis and monitoring.

• #86 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This approach may prove beneficial in cases where surgery is not possible or in cases of adult diffuse glioma recurrence. […] Finally, in the study of Palande et al., gene mutations and gene–gene fusions were detected in the circulating cfDNA of patients with GB. […] This study utilized the ChiTaRS 5.0 gene–gene fusion database to identify gene–gene fusions in cfDNA and tumor DNA samples. […] Notably, fusions involving PDGFRA were found in 44% of GB samples, which can be effectively targeted using tyrosine kinase inhibitors. […] The combination of liquid biopsy and radiomics/radiogenomics can offer a promising avenue for non-invasive disease diagnosis and provide valuable insights for treatment planning. […] The extension of this approach to gliomas represents a significant opportunity to improve the accuracy and efficiency of non-invasive diagnosis and monitoring.

• #87 Glioblastoma (Multiforme) Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/340870-overview

  Although a formal diagnosis of glioblastoma relies on histopathology and genetic markers for grading, structural MRIs are routinely performed and can be used to help guide surgery. […] After surgery, differentiating between recurrent tumor and scar tissue on the basis of MRI findings alone may be difficult. […] The National Comprehensive Cancer Network (NCCN) guidelines consider magnetic resonance imaging (MRI) of the brain to be the gold standard imaging study for glioblastoma. […] CT scan results offer a relatively high degree of confidence for the diagnosis of glioblastoma. […] MRI has a high degree of confidence in the diagnosis of glioblastoma and is widely used for identifying location and size of brain tumors. […] Positron emission tomography (PET) scanning is a useful adjunct to the evaluation of glioblastoma, particularly after resection. […] Angiographic findings associated with glioblastoma include the following: hypervascular mass with tumor blush; prominent feeding and draining vessels, as well as arteriovenous shunting (this may mimic an arteriovenous malformation).

• #88 Glioblastoma (Multiforme) Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/340870-overview

  Although a formal diagnosis of glioblastoma relies on histopathology and genetic markers for grading, structural MRIs are routinely performed and can be used to help guide surgery. […] After surgery, differentiating between recurrent tumor and scar tissue on the basis of MRI findings alone may be difficult. […] The National Comprehensive Cancer Network (NCCN) guidelines consider magnetic resonance imaging (MRI) of the brain to be the gold standard imaging study for glioblastoma. […] CT scan results offer a relatively high degree of confidence for the diagnosis of glioblastoma. […] MRI has a high degree of confidence in the diagnosis of glioblastoma and is widely used for identifying location and size of brain tumors. […] Positron emission tomography (PET) scanning is a useful adjunct to the evaluation of glioblastoma, particularly after resection. […] Angiographic findings associated with glioblastoma include the following: hypervascular mass with tumor blush; prominent feeding and draining vessels, as well as arteriovenous shunting (this may mimic an arteriovenous malformation).

• #89 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  When evaluating a patient with a suspected glioma, it is crucial to consider a range of differential diagnoses to ensure accurate diagnosis and appropriate treatment. […] Several techniques have been used to increase the extent of resection of gliomas, including intraoperative MRI and fluorescein-guided resections. […] Postoperative radiation therapy aims to eliminate residual tumor cells, reduce recurrence risk, and prolong survival. […] The prognosis of patients with gliomas depends on several factors, as follows: Age of the patient, Comorbidities, Grade and location of the tumor, Presence of hydrocephalus, Response to adjuvant therapy, Extent of surgical resection. […] Patients with gliomas benefit from consultations with a multidisciplinary team of specialists to ensure comprehensive and personalized care. […] Deterrence and patient education are crucial components in managing gliomas, aiming to improve patient outcomes and quality of life.

• #90 Diffuse Midline Glioma: Diagnosis and Treatment – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/tumors/diffuse-midline-gliomas

  To get an accurate diagnosis, a piece of tumor tissue will be removed during surgery, if possible. A neuropathologist should then review the tumor tissue. […] Diffuse midline gliomas are all grade 4 (also written as grade IV). This means they are malignant (cancerous) and fast-growing. […] In adults, a diffuse midline glioma diagnosis cant be made by imaging alone, because the tumors look similar to glioblastomas and other high-grade brain cancers. […] Because it can be hard to tell them apart, molecular testing is required. Some diffuse midline gliomas have changes in histone-related genes. The most common gene is h3K27M. A neuropathologist should confirm the diagnosis. […] The first treatment for diffuse midline glioma is surgery, if possible. The goal of surgery is to obtain tissue to determine the tumor type and remove as much tumor as possible without causing more symptoms. […] A team of experts including neuro-oncologists, neuroradiologists, radiation oncologists, and neurosurgeons should review the tumor to determine the best treatment plan.

• #91 Glioma Diagnosis and Classification: Illuminating the Gold Standard | SpringerLink

  https://link.springer.com/chapter/10.1007/978-3-030-72084-1_1

  Accurate glioma classification is essential for optimal patient care, and requires integration of histological and immunohistochemical findings with molecular features, in the context of imaging and demographic information. […] This paper will introduce classic histologic features of gliomas in contrast to nonneoplastic brain parenchyma, describe the basic clinical algorithm used to classify infiltrating gliomas, and demonstrate how the classification is reflected in the diagnostic reporting structure. […] Key molecular features include IDH mutational status and 1p/19q codeletion. […] In addition, molecular changes may indicate poor prognosis despite lower grade histology, such as findings consistent with two grade IV infiltrating gliomas: molecular glioblastoma and diffuse midline gliomas. […] Detailed molecular characterization aids in optimization of treatment with the goal of improved patient outcomes.

• #92 Glioma Markers for High-Grade Gliomas and Low-Grade Gliomas

  https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/immunohistochemistry/glioma-markers-for-high-grade-gliomas-and-low-grade-gliomas?srsltid=AfmBOoolajhUPZIg85Xfef_EzKdvdDGjggLZLfG1pfWj5epsfGj_4WIk

  Unfortunately, the prognosis for high-grade gliomas is poor due to limited possibilities of curative treatment. […] Gliomas are well-known tumors at the molecular level. […] While our knowledge about the molecular biology of gliomas is rapidly expanding and is, to some extent, already assisting us in the design of tumor-tailored therapeutics, such as immunotherapy treatments, we are still struggling to develop efficient treatments. […] As a result, the overall survival rate of gliomas has not significantly increased in the last decades. […] Due to the absence of definitive surgical and medical treatments currently available, an early diagnosis coupled with an accurate tumor classification is crucial to select a personalized treatment. […] Therefore, the identification of molecular biomarkers is unquestionably essential and urgent for an accurate prognosis and development of critical therapeutic targets in gliomas.

• #93 Glioma vs. glioblastoma: What’s the difference? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/glioma-vs–glioblastoma–what-is-the-difference-in-these-brain-tumors-treatment-diagnosis.h00-159537378.html

  Certain genetic features can distinguish between different kinds of gliomas. Physicians test for IDH, an enzyme that affects metabolism in the cancer cells. Testing is also done for the genetic marker 1p19q, which helps distinguish oligodendroglioma and astrocytoma. […] After completing treatment for glioma, patients undergo regular MRIs to make sure their tumor has not recurred. How often a patient is seen varies, depending on their diagnosis and treatment plan. […] It’s important to make that distinction because these advances identify different prognoses and different optimal treatment options for patients.

• #94 Glioma vs. glioblastoma: What’s the difference? | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/glioma-vs–glioblastoma–what-is-the-difference-in-these-brain-tumors-treatment-diagnosis.h00-159537378.html

  Certain genetic features can distinguish between different kinds of gliomas. Physicians test for IDH, an enzyme that affects metabolism in the cancer cells. Testing is also done for the genetic marker 1p19q, which helps distinguish oligodendroglioma and astrocytoma. […] After completing treatment for glioma, patients undergo regular MRIs to make sure their tumor has not recurred. How often a patient is seen varies, depending on their diagnosis and treatment plan. […] It’s important to make that distinction because these advances identify different prognoses and different optimal treatment options for patients.

• #95 Managing Your Glioma Cancer Treatment | My Glioma Guide

  https://www.mygliomaguide.com/managing-glioma

  You and your healthcare team will create a treatment plan tailored to your needs and preferences. […] Follow-up appointments, including brain scans, are a vital part of your treatment plan. […] A glioma diagnosis may require you to make some adjustments in your life. […] You and your doctor will develop a treatment plan that is targeted to your cancer. […] Once you have received the results of your brain scans, your physician will determine if you are eligible for surgery. […] After your surgery, your doctor will perform additional tests to determine the appropriate next steps in your treatment. […] Follow-up appointments, including imaging, are important for anyone managing glioma. […] Be sure to make time for your brain scan appointments on the schedule your doctor gives you. […] The follow-up appointments are usually more frequent in the beginning of your treatment, and may become less so as time goes on.

• #96 Managing Your Glioma Cancer Treatment | My Glioma Guide

  https://www.mygliomaguide.com/managing-glioma

  You and your healthcare team will create a treatment plan tailored to your needs and preferences. […] Follow-up appointments, including brain scans, are a vital part of your treatment plan. […] A glioma diagnosis may require you to make some adjustments in your life. […] You and your doctor will develop a treatment plan that is targeted to your cancer. […] Once you have received the results of your brain scans, your physician will determine if you are eligible for surgery. […] After your surgery, your doctor will perform additional tests to determine the appropriate next steps in your treatment. […] Follow-up appointments, including imaging, are important for anyone managing glioma. […] Be sure to make time for your brain scan appointments on the schedule your doctor gives you. […] The follow-up appointments are usually more frequent in the beginning of your treatment, and may become less so as time goes on.

• #97 Understanding Glioma Diagnosis: How Doctors Use MRI and Pathology to Guide Treatment Options – SurvivorNet

  https://www.survivornet.com/articles/understanding-glioma-diagnosis-how-doctors-use-mri-and-pathology-to-guide-treatment-options/

  The location of a glioma plays a critical role in determining whether it can be surgically removed. […] Once treatment has begun, MRI scans are used regularly to track changes in the tumor. This helps doctors determine if therapies are working or if adjustments are needed. […] While MRI provides critical information about the structure and behavior of a glioma, examining the tumor under a microscope remains the gold standard for diagnosis. […] Knowing the grade of your tumor helps your doctor decide on the most effective treatment approach. […] In addition to traditional pathology, molecular testing has become increasingly important in glioma diagnosis and treatment. […] Understanding your glioma and the tools used to diagnose and monitor it empowers you to make informed decisions about your care.

• #98 Glioblastoma (Multiforme) Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging

  https://emedicine.medscape.com/article/340870-overview

  Although a formal diagnosis of glioblastoma relies on histopathology and genetic markers for grading, structural MRIs are routinely performed and can be used to help guide surgery. […] After surgery, differentiating between recurrent tumor and scar tissue on the basis of MRI findings alone may be difficult. […] The National Comprehensive Cancer Network (NCCN) guidelines consider magnetic resonance imaging (MRI) of the brain to be the gold standard imaging study for glioblastoma. […] CT scan results offer a relatively high degree of confidence for the diagnosis of glioblastoma. […] MRI has a high degree of confidence in the diagnosis of glioblastoma and is widely used for identifying location and size of brain tumors. […] Positron emission tomography (PET) scanning is a useful adjunct to the evaluation of glioblastoma, particularly after resection. […] Angiographic findings associated with glioblastoma include the following: hypervascular mass with tumor blush; prominent feeding and draining vessels, as well as arteriovenous shunting (this may mimic an arteriovenous malformation).

• #99 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  MRI is the current diagnostic and monitoring standard for newly diagnosed and recurrent gliomas. […] The challenge here is overcoming the consequential uncertainty in outcome evaluation prior to stabilisation: to alter the course of therapy or to do nothing at all? It would be useful to establish biomarkers unique to gliomas that would aid in these differentiations. […] A single, reliable diagnostic biomarker would be abundantly expressed within the tumour across all stages and in the majority of patients with glioma. […] There is a need for biomarkers unique to patients with glioma that are either expressed abundantly in the bloodstream or able to surpass the BBB for adequate detection. […] The molecular and cellular complexity of gliomas significantly limits diagnosis and treatment. […] There is an urgent need for biomarkers that (1) aid in diagnosis and patient stratification, (2) identify true disease recurrence, and (3) indicate response to treatment.

• #100 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. […] There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood-brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. […] This is a review summarising and evaluating the current genetic, proteomic and cellular biomarkers of glioma, discussing major hurdles to overcome in glioma diagnostics and treatment. […] The current median survival time for patients with glioblastoma is approximately 14-15 months post-diagnosis with treatment and 3-4 months without treatment.

• #101 What is Glioblastoma? Symptoms, Risk Factors & Treatments | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/glioblastoma.html

  A single tumor contains many different types of cells, so a drug that works for some cells may not successfully treat the entire tumor. […] During brain surgery, neurosurgeons strive to remove as much of the tumor as possible without damaging the parts of the brain that control these functions. […] Delivering medications to the brain is also difficult. The blood vessels for the central nervous system (CNS) are designed to stop diseases and toxins in the blood from reaching this area, which includes the brain and spinal cord. […] Known as the blood brain barrier, this feature protects the brain, but it also stops many drugs from getting to brain tumors. […] At MD Anderson, we have the most sophisticated equipment available to identify brain tumors and find out exactly how far they may have spread in the central nervous system.

• #102 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  MRI is the current diagnostic and monitoring standard for newly diagnosed and recurrent gliomas. […] The challenge here is overcoming the consequential uncertainty in outcome evaluation prior to stabilisation: to alter the course of therapy or to do nothing at all? It would be useful to establish biomarkers unique to gliomas that would aid in these differentiations. […] A single, reliable diagnostic biomarker would be abundantly expressed within the tumour across all stages and in the majority of patients with glioma. […] There is a need for biomarkers unique to patients with glioma that are either expressed abundantly in the bloodstream or able to surpass the BBB for adequate detection. […] The molecular and cellular complexity of gliomas significantly limits diagnosis and treatment. […] There is an urgent need for biomarkers that (1) aid in diagnosis and patient stratification, (2) identify true disease recurrence, and (3) indicate response to treatment.

• #103 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  MRI is the current diagnostic and monitoring standard for newly diagnosed and recurrent gliomas. […] The challenge here is overcoming the consequential uncertainty in outcome evaluation prior to stabilisation: to alter the course of therapy or to do nothing at all? It would be useful to establish biomarkers unique to gliomas that would aid in these differentiations. […] A single, reliable diagnostic biomarker would be abundantly expressed within the tumour across all stages and in the majority of patients with glioma. […] There is a need for biomarkers unique to patients with glioma that are either expressed abundantly in the bloodstream or able to surpass the BBB for adequate detection. […] The molecular and cellular complexity of gliomas significantly limits diagnosis and treatment. […] There is an urgent need for biomarkers that (1) aid in diagnosis and patient stratification, (2) identify true disease recurrence, and (3) indicate response to treatment.

• #104 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. […] There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood-brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. […] This is a review summarising and evaluating the current genetic, proteomic and cellular biomarkers of glioma, discussing major hurdles to overcome in glioma diagnostics and treatment. […] The current median survival time for patients with glioblastoma is approximately 14-15 months post-diagnosis with treatment and 3-4 months without treatment.

• #105 What is Glioblastoma? Symptoms, Risk Factors & Treatments | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/glioblastoma.html

  A single tumor contains many different types of cells, so a drug that works for some cells may not successfully treat the entire tumor. […] During brain surgery, neurosurgeons strive to remove as much of the tumor as possible without damaging the parts of the brain that control these functions. […] Delivering medications to the brain is also difficult. The blood vessels for the central nervous system (CNS) are designed to stop diseases and toxins in the blood from reaching this area, which includes the brain and spinal cord. […] Known as the blood brain barrier, this feature protects the brain, but it also stops many drugs from getting to brain tumors. […] At MD Anderson, we have the most sophisticated equipment available to identify brain tumors and find out exactly how far they may have spread in the central nervous system.

• #106 What is Glioblastoma? Symptoms, Risk Factors & Treatments | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/glioblastoma.html

  A single tumor contains many different types of cells, so a drug that works for some cells may not successfully treat the entire tumor. […] During brain surgery, neurosurgeons strive to remove as much of the tumor as possible without damaging the parts of the brain that control these functions. […] Delivering medications to the brain is also difficult. The blood vessels for the central nervous system (CNS) are designed to stop diseases and toxins in the blood from reaching this area, which includes the brain and spinal cord. […] Known as the blood brain barrier, this feature protects the brain, but it also stops many drugs from getting to brain tumors. […] At MD Anderson, we have the most sophisticated equipment available to identify brain tumors and find out exactly how far they may have spread in the central nervous system.

• #107 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  MRI is the current diagnostic and monitoring standard for newly diagnosed and recurrent gliomas. […] The challenge here is overcoming the consequential uncertainty in outcome evaluation prior to stabilisation: to alter the course of therapy or to do nothing at all? It would be useful to establish biomarkers unique to gliomas that would aid in these differentiations. […] A single, reliable diagnostic biomarker would be abundantly expressed within the tumour across all stages and in the majority of patients with glioma. […] There is a need for biomarkers unique to patients with glioma that are either expressed abundantly in the bloodstream or able to surpass the BBB for adequate detection. […] The molecular and cellular complexity of gliomas significantly limits diagnosis and treatment. […] There is an urgent need for biomarkers that (1) aid in diagnosis and patient stratification, (2) identify true disease recurrence, and (3) indicate response to treatment.

• #108 Diagnosing Glioma | Expert Surgeon | Aaron Cohen-Gadol, MD

  https://www.aaroncohen-gadol.com/en/patients/glioma/natural-history/diagnosing

  A physical exam alone will not diagnose glioma. However, health providers will use the physical exam to guide further diagnostic decisions. […] CT scans are a common first step in diagnosing a glioma. However, physicians often move on to another, more advanced scan, like an MRI. […] After looking at a CT scan, physicians may order an MRI to get a closer look at a potential glioma. […] Once your physician has found a tumor and you have been referred to a neurosurgeon, the neurosurgeon may decide to perform a biopsy to finalize the diagnosis before making a more definitive decision for removal of the tumor through a craniotomy. […] As some brain tumors can look alike on MRI, further testing such as a biopsy is needed for final accurate diagnosis. […] Depending on the glioma grade, physicians might perform more diagnostic tests to improve their treatment decisions. […] Diagnosing a glioma can be a journey. Physicians will combine physical examination results with advanced procedures like an MRI and biopsy to make a definitive diagnosis. […] Unfortunately, many gliomas are diagnosed in their higher grades as an early diagnosis is not possible.

• #109 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #110 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #111 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #112 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #113 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  Gliomas are a diverse group of tumors originating from glial cells in the brain and spinal cord, representing the most common primary brain tumor within the central nervous system. In the United States, there are 6 cases of gliomas diagnosed per 100,000 individuals every year. […] Advances in molecular and genetic research have led to improved diagnostic accuracy and the development of targeted therapies. Despite these advancements, the diffuse and infiltrative nature of high-grade gliomas poses ongoing challenges in treatment and management. […] This activity reviews the pathophysiology, clinical presentations, and diagnostic techniques of glioma and provides the knowledge and skills to diagnose, treat, and manage patients with gliomas. […] Identify early signs and symptoms of gliomas, such as new-onset headaches, seizures, cognitive deficits, or focal neurological deficits, to facilitate timely diagnosis and intervention. […] Differentiate between various types of gliomas based on histopathological characteristics, molecular markers, and imaging findings to guide appropriate treatment strategies. […] Implement evidence-based treatment protocols tailored to the specific type and grade of glioma, incorporating the latest advances in medical research.

• #114 Glioma: What Is It, Causes, Symptoms, Treatment & Outlook

  https://my.clevelandclinic.org/health/diseases/21969-glioma

  Your treatment plan for a glioma depends on several factors, including: If youve had brain cancer treatment in the past. […] For most people, surgery is the first treatment for a glioma. […] Additional treatments, such as chemotherapy and radiation therapy, should follow surgery. […] A craniotomy (open brain surgery) is the most common type of surgery to remove gliomas. […] Radiation therapy uses powerful doses of radiation to destroy tumors. […] Chemotherapy is the use of drugs to destroy cancer cells. […] Most risk factors for gliomas, such as age and race, arent controllable. […] Survival rates for gliomas vary by tumor type, tumor grade and a persons age. […] After treatment, stay in close communication with your healthcare provider. […] Gliomas are tumors that form in glial cells in the brain and spinal cord. Theyre usually cancerous.

• #115 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  Gliomas are a diverse group of tumors originating from glial cells in the brain and spinal cord, representing the most common primary brain tumor within the central nervous system. In the United States, there are 6 cases of gliomas diagnosed per 100,000 individuals every year. […] Advances in molecular and genetic research have led to improved diagnostic accuracy and the development of targeted therapies. Despite these advancements, the diffuse and infiltrative nature of high-grade gliomas poses ongoing challenges in treatment and management. […] This activity reviews the pathophysiology, clinical presentations, and diagnostic techniques of glioma and provides the knowledge and skills to diagnose, treat, and manage patients with gliomas. […] Identify early signs and symptoms of gliomas, such as new-onset headaches, seizures, cognitive deficits, or focal neurological deficits, to facilitate timely diagnosis and intervention. […] Differentiate between various types of gliomas based on histopathological characteristics, molecular markers, and imaging findings to guide appropriate treatment strategies. […] Implement evidence-based treatment protocols tailored to the specific type and grade of glioma, incorporating the latest advances in medical research.

• #116 Glioma: What Is It, Causes, Symptoms, Treatment & Outlook

  https://my.clevelandclinic.org/health/diseases/21969-glioma

  Your treatment plan for a glioma depends on several factors, including: If youve had brain cancer treatment in the past. […] For most people, surgery is the first treatment for a glioma. […] Additional treatments, such as chemotherapy and radiation therapy, should follow surgery. […] A craniotomy (open brain surgery) is the most common type of surgery to remove gliomas. […] Radiation therapy uses powerful doses of radiation to destroy tumors. […] Chemotherapy is the use of drugs to destroy cancer cells. […] Most risk factors for gliomas, such as age and race, arent controllable. […] Survival rates for gliomas vary by tumor type, tumor grade and a persons age. […] After treatment, stay in close communication with your healthcare provider. […] Gliomas are tumors that form in glial cells in the brain and spinal cord. Theyre usually cancerous.

• #117 Diffuse Midline Glioma: Diagnosis and Treatment – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/tumors/diffuse-midline-gliomas

  To get an accurate diagnosis, a piece of tumor tissue will be removed during surgery, if possible. A neuropathologist should then review the tumor tissue. […] Diffuse midline gliomas are all grade 4 (also written as grade IV). This means they are malignant (cancerous) and fast-growing. […] In adults, a diffuse midline glioma diagnosis cant be made by imaging alone, because the tumors look similar to glioblastomas and other high-grade brain cancers. […] Because it can be hard to tell them apart, molecular testing is required. Some diffuse midline gliomas have changes in histone-related genes. The most common gene is h3K27M. A neuropathologist should confirm the diagnosis. […] The first treatment for diffuse midline glioma is surgery, if possible. The goal of surgery is to obtain tissue to determine the tumor type and remove as much tumor as possible without causing more symptoms. […] A team of experts including neuro-oncologists, neuroradiologists, radiation oncologists, and neurosurgeons should review the tumor to determine the best treatment plan.

• #118 What is Glioblastoma? Symptoms, Risk Factors & Treatments | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/glioblastoma.html

  The process of diagnosing glioblastoma is essentially the same as testing for other brain tumors. […] If you have symptoms that signal a brain tumor, your doctor will examine you and ask questions about your health, your lifestyle and your familys medical history. […] If the doctor decides further testing is needed, he or she will order an imaging exam. One or more of the following tests may be used to find out if you have a brain tumor. […] Tissue samples are obtained by a biopsy. For glioblastoma, a tissue sample is usually retrieved during surgery to remove the tumor. […] A pathologist will then examine the cells to make a diagnosis. […] Glioblastoma with the MGMT promoter methylation mutation may respond better to treatment. […] The standard treatment for glioblastoma starts with surgery to remove as much of the tumor as safely as possible.

• #119 Glioma: What Is It, Causes, Symptoms, Treatment & Outlook

  https://my.clevelandclinic.org/health/diseases/21969-glioma

  Your treatment plan for a glioma depends on several factors, including: If youve had brain cancer treatment in the past. […] For most people, surgery is the first treatment for a glioma. […] Additional treatments, such as chemotherapy and radiation therapy, should follow surgery. […] A craniotomy (open brain surgery) is the most common type of surgery to remove gliomas. […] Radiation therapy uses powerful doses of radiation to destroy tumors. […] Chemotherapy is the use of drugs to destroy cancer cells. […] Most risk factors for gliomas, such as age and race, arent controllable. […] Survival rates for gliomas vary by tumor type, tumor grade and a persons age. […] After treatment, stay in close communication with your healthcare provider. […] Gliomas are tumors that form in glial cells in the brain and spinal cord. Theyre usually cancerous.

• #120 Navigating a Glioma Diagnosis: Understanding Your Tumor Type & Treatment Options – SurvivorNet

  https://www.survivornet.com/articles/navigating-a-glioma-diagnosis-understanding-your-tumor-type-treatment-options/

  Navigating a Glioma Diagnosis: Understanding Your Tumor Type & Treatment Options […] Gliomas can develop from several different types of cells in the brain, including oligodendrocytes, astrocytes, and ependymal cells. […] The treatment path may vary depending on what type of brain cell has developed the glioma. Astrocytoma tends to be a bit more aggressive. […] The treatment approach for all types of glioma may involve surgery, chemotherapy, and radiation. […] Newer approaches, such as targeted therapy or tumor treating fields, may be recommended for some patients. […] IDH targeting therapy with vorasidenib for low grade oligo and astrocytoma with IDH mutations should be discussed with your doctor. […] Many factors go into a glioma diagnosis — this may include a close evaluation of the tumor, a grading process, and molecular testing. Categorizing the tumor helps your doctor determine the best course of treatment.

• #121 Navigating a Glioma Diagnosis: Understanding Your Tumor Type & Treatment Options – SurvivorNet

  https://www.survivornet.com/articles/navigating-a-glioma-diagnosis-understanding-your-tumor-type-treatment-options/

  Navigating a Glioma Diagnosis: Understanding Your Tumor Type & Treatment Options […] Gliomas can develop from several different types of cells in the brain, including oligodendrocytes, astrocytes, and ependymal cells. […] The treatment path may vary depending on what type of brain cell has developed the glioma. Astrocytoma tends to be a bit more aggressive. […] The treatment approach for all types of glioma may involve surgery, chemotherapy, and radiation. […] Newer approaches, such as targeted therapy or tumor treating fields, may be recommended for some patients. […] IDH targeting therapy with vorasidenib for low grade oligo and astrocytoma with IDH mutations should be discussed with your doctor. […] Many factors go into a glioma diagnosis — this may include a close evaluation of the tumor, a grading process, and molecular testing. Categorizing the tumor helps your doctor determine the best course of treatment.

• #122 Glioma Markers for High-Grade Gliomas and Low-Grade Gliomas

  https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/immunohistochemistry/glioma-markers-for-high-grade-gliomas-and-low-grade-gliomas?srsltid=AfmBOoolajhUPZIg85Xfef_EzKdvdDGjggLZLfG1pfWj5epsfGj_4WIk

  Unfortunately, the prognosis for high-grade gliomas is poor due to limited possibilities of curative treatment. […] Gliomas are well-known tumors at the molecular level. […] While our knowledge about the molecular biology of gliomas is rapidly expanding and is, to some extent, already assisting us in the design of tumor-tailored therapeutics, such as immunotherapy treatments, we are still struggling to develop efficient treatments. […] As a result, the overall survival rate of gliomas has not significantly increased in the last decades. […] Due to the absence of definitive surgical and medical treatments currently available, an early diagnosis coupled with an accurate tumor classification is crucial to select a personalized treatment. […] Therefore, the identification of molecular biomarkers is unquestionably essential and urgent for an accurate prognosis and development of critical therapeutic targets in gliomas.

• #123 Glioma Markers for High-Grade Gliomas and Low-Grade Gliomas

  https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/immunohistochemistry/glioma-markers-for-high-grade-gliomas-and-low-grade-gliomas?srsltid=AfmBOoolajhUPZIg85Xfef_EzKdvdDGjggLZLfG1pfWj5epsfGj_4WIk

  Unfortunately, the prognosis for high-grade gliomas is poor due to limited possibilities of curative treatment. […] Gliomas are well-known tumors at the molecular level. […] While our knowledge about the molecular biology of gliomas is rapidly expanding and is, to some extent, already assisting us in the design of tumor-tailored therapeutics, such as immunotherapy treatments, we are still struggling to develop efficient treatments. […] As a result, the overall survival rate of gliomas has not significantly increased in the last decades. […] Due to the absence of definitive surgical and medical treatments currently available, an early diagnosis coupled with an accurate tumor classification is crucial to select a personalized treatment. […] Therefore, the identification of molecular biomarkers is unquestionably essential and urgent for an accurate prognosis and development of critical therapeutic targets in gliomas.

• #124 Glioma & Glioblastoma Symptoms, Diagnosis and Treatment | Pacific Brain Tumor Center

  https://www.pacificneuroscienceinstitute.org/brain-tumor/conditions/gliomas/

  The treatment of a glioma depends tremendously on the tumor WHO grade and subtype, as well as size and location of the tumor. […] At the current time, it is not possible to obtain a cure of an infiltrative or high-grade glioma (Grade III or IV). […] Because gliomas are infiltrative into the brain and blend into the adjacent normal brain, they typically cannot be removed completely. […] Treatment for gliomas can be surgical or non-surgical. One of the key principles we focus on is maximal tumor removal with preservation of quality of life and neurological function. […] The current standard of therapy for newly-diagnosed high grade gliomas (WHO Grade III or IV) typically include 6 weeks of chemotherapy using a drug called temozolamide, in conjunction with radiation therapy followed by additional chemotherapy cycles. […] Personalized therapy options based on molecular and genetic profiling of the tumor also allow PNI to determine treatments that are individualized for each patient.

• #125 Understanding Glioma Diagnosis: How Doctors Use MRI and Pathology to Guide Treatment Options – SurvivorNet

  https://www.survivornet.com/articles/understanding-glioma-diagnosis-how-doctors-use-mri-and-pathology-to-guide-treatment-options/

  The location of a glioma plays a critical role in determining whether it can be surgically removed. […] Once treatment has begun, MRI scans are used regularly to track changes in the tumor. This helps doctors determine if therapies are working or if adjustments are needed. […] While MRI provides critical information about the structure and behavior of a glioma, examining the tumor under a microscope remains the gold standard for diagnosis. […] Knowing the grade of your tumor helps your doctor decide on the most effective treatment approach. […] In addition to traditional pathology, molecular testing has become increasingly important in glioma diagnosis and treatment. […] Understanding your glioma and the tools used to diagnose and monitor it empowers you to make informed decisions about your care.

• #126 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This approach may prove beneficial in cases where surgery is not possible or in cases of adult diffuse glioma recurrence. […] Finally, in the study of Palande et al., gene mutations and gene–gene fusions were detected in the circulating cfDNA of patients with GB. […] This study utilized the ChiTaRS 5.0 gene–gene fusion database to identify gene–gene fusions in cfDNA and tumor DNA samples. […] Notably, fusions involving PDGFRA were found in 44% of GB samples, which can be effectively targeted using tyrosine kinase inhibitors. […] The combination of liquid biopsy and radiomics/radiogenomics can offer a promising avenue for non-invasive disease diagnosis and provide valuable insights for treatment planning. […] The extension of this approach to gliomas represents a significant opportunity to improve the accuracy and efficiency of non-invasive diagnosis and monitoring.

• #127 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This approach may prove beneficial in cases where surgery is not possible or in cases of adult diffuse glioma recurrence. […] Finally, in the study of Palande et al., gene mutations and gene–gene fusions were detected in the circulating cfDNA of patients with GB. […] This study utilized the ChiTaRS 5.0 gene–gene fusion database to identify gene–gene fusions in cfDNA and tumor DNA samples. […] Notably, fusions involving PDGFRA were found in 44% of GB samples, which can be effectively targeted using tyrosine kinase inhibitors. […] The combination of liquid biopsy and radiomics/radiogenomics can offer a promising avenue for non-invasive disease diagnosis and provide valuable insights for treatment planning. […] The extension of this approach to gliomas represents a significant opportunity to improve the accuracy and efficiency of non-invasive diagnosis and monitoring.

• #128 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis | BMJ Neurology Open

  https://neurologyopen.bmj.com/content/2/2/e000069

  Conventional diagnosis of glioblastoma is made based on clinical presentation, MRI and histopathological analysis. […] An advantage of molecular diagnosis is the potential for developing patient-specific therapies that target various oncogenic pathways. […] Current therapeutics for gliomas are limited and only offer a modest prognostic benefit. […] The standard of care involves maximal safe surgical resection and radiotherapy with concomitant chemotherapy. […] Despite treatment, the 5-year survival rate is 5% for glioblastoma and 30% for patients with anaplastic astrocytoma. […] It is evident that gliomas present a critically high, unmet clinical need; hence, the development of more effective therapeutics is pivotal. […] There is a desperate need for improvement in both glioma diagnosis and treatment.

• #129 Understanding Glioma Diagnosis: How Doctors Use MRI and Pathology to Guide Treatment Options – SurvivorNet

  https://www.survivornet.com/articles/understanding-glioma-diagnosis-how-doctors-use-mri-and-pathology-to-guide-treatment-options/

  The location of a glioma plays a critical role in determining whether it can be surgically removed. […] Once treatment has begun, MRI scans are used regularly to track changes in the tumor. This helps doctors determine if therapies are working or if adjustments are needed. […] While MRI provides critical information about the structure and behavior of a glioma, examining the tumor under a microscope remains the gold standard for diagnosis. […] Knowing the grade of your tumor helps your doctor decide on the most effective treatment approach. […] In addition to traditional pathology, molecular testing has become increasingly important in glioma diagnosis and treatment. […] Understanding your glioma and the tools used to diagnose and monitor it empowers you to make informed decisions about your care.

• #130 What is Glioblastoma? Symptoms, Risk Factors & Treatments | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/glioblastoma.html

  The process of diagnosing glioblastoma is essentially the same as testing for other brain tumors. […] If you have symptoms that signal a brain tumor, your doctor will examine you and ask questions about your health, your lifestyle and your familys medical history. […] If the doctor decides further testing is needed, he or she will order an imaging exam. One or more of the following tests may be used to find out if you have a brain tumor. […] Tissue samples are obtained by a biopsy. For glioblastoma, a tissue sample is usually retrieved during surgery to remove the tumor. […] A pathologist will then examine the cells to make a diagnosis. […] Glioblastoma with the MGMT promoter methylation mutation may respond better to treatment. […] The standard treatment for glioblastoma starts with surgery to remove as much of the tumor as safely as possible.

• #131 Diagnosis and Management of Glioblastoma: A Comprehensive Perspective

  https://www.mdpi.com/2075-4426/11/4/258

  Glioblastoma is the most common malignant brain tumor in adults. The current management relies on surgical resection and adjuvant radiotherapy and chemotherapy. […] In a recent article based on a prospective registry of central nervous system (CNS) tumors in the US, glioblastoma accounts for 54% of brain gliomas with an annual incidence of 3.19 per 100,000. […] The diagnosis of glioblastoma is easily made on surgical resections or biopsy samples. Glioblastomas are high grade gliomas, grade IV according to the World Health Organization (WHO) classification of the central nervous system tumors. […] The standard of care for patients aged less than 70 relies on radiotherapy (RT) and adjuvant temozolomide. […] The disease progression is evaluated using brain MRI every 2 to 3 months according to the response assessment in Neuro-oncology (RANO) criteria.

• #132 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  Imaging diagnostics are appropriate for evaluating suspected brain tumors and include the following: […] Magnetic resonance imaging (brain): This is the most sensitive study to determine the characteristics of brain tumors. Low-grade tumors usually do not enhance, while high-grade tumors have varying degrees of enhancement. […] The WHO classification of gliomas is used to guide treatment. As indicated in the classification, most patients will require surgical intervention via maximally safe resection or stereotactic-guided biopsy. […] Surgical resection is the mainstay of treatment with a goal of maximal safe resection, depending on tumor grading and location. […] Current acceptable practices include a maximal safe resection and the possibility of gross total resection, with radiographic follow-up. […] Maximal safe resection, concomitant chemoradiation, and radiographic follow-up for recurrence is an acceptable treatment.

• #133 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This technique provides vital diagnostic and prognostic information, as well as real-time updates on tumor status. […] In the case of gliomas, the use of a liquid biopsy is extremely promising. […] LB has allowed the detection of cfDNA in cancer patients, as mentioned above, which has created the potential of its incorporation into clinical practice, with the goal of identifying both genetic and epigenetic alterations in tumors. […] cfDNA may be a suitable molecular marker, indicative of tumor status, which will enable disease monitoring and distinction between tumor-free individuals and brain tumor patients. […] One study demonstrated that the serum of control subjects was consistently characterized by low levels of cfDNA, in contrast to GB patients who had higher cfDNA concentrations.

• #134 New Blood Test Enables Minimally Invasive Glioma Diagnosis | Clinical Lab Products

  https://clpmag.com/diagnostic-technologies/molecular-diagnostics/new-blood-test-enables-minimally-invasive-glioma-diagnosis/

  Results from our plasma testing demonstrate an overall sensitivity of 75.0%, specificity 88.7%, positive predictive value 90.9%, and negative predictive value 70.1% compared to the tissue gold standard. […] Detection of the IDH1 mutation in blood means that these tumors can be diagnosed without a biopsy, and can be monitored overtime to track disease progression, response to treatment or recurrence using a simple blood sample. […] Importantly, the FDA recently approved a drug (vorasidenib) for this mutation in glioma this means that the test, once approved, can be used to stratify these patients for this treatment and can monitor disease course.

• #135 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  This approach may prove beneficial in cases where surgery is not possible or in cases of adult diffuse glioma recurrence. […] Finally, in the study of Palande et al., gene mutations and gene–gene fusions were detected in the circulating cfDNA of patients with GB. […] This study utilized the ChiTaRS 5.0 gene–gene fusion database to identify gene–gene fusions in cfDNA and tumor DNA samples. […] Notably, fusions involving PDGFRA were found in 44% of GB samples, which can be effectively targeted using tyrosine kinase inhibitors. […] The combination of liquid biopsy and radiomics/radiogenomics can offer a promising avenue for non-invasive disease diagnosis and provide valuable insights for treatment planning. […] The extension of this approach to gliomas represents a significant opportunity to improve the accuracy and efficiency of non-invasive diagnosis and monitoring.

• #136 Glioma Markers for High-Grade Gliomas and Low-Grade Gliomas

  https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/immunohistochemistry/glioma-markers-for-high-grade-gliomas-and-low-grade-gliomas?srsltid=AfmBOoolajhUPZIg85Xfef_EzKdvdDGjggLZLfG1pfWj5epsfGj_4WIk

  Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. […] Nowadays, several approaches aim to understand the biology of the disease and identify promising markers, which may provide effective novel therapies. […] This article summarizes some developments in glioma classification and the key molecular markers for glioma stratification, highlights the glioma proteome through a list of relevant genes with favorable and unfavorable prognostic values in glioma, and focuses on the glioma tumor microenvironment that may provide helpful insights when developing novel therapeutic strategies. […] Survival time after diagnosis with glioma varies significantly depending on grade. […] According to the World Health Organization (WHO) classification, gliomas are divided into four grades.

• #137 Glioma Markers for High-Grade Gliomas and Low-Grade Gliomas

  https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/protein-biology/immunohistochemistry/glioma-markers-for-high-grade-gliomas-and-low-grade-gliomas?srsltid=AfmBOoolajhUPZIg85Xfef_EzKdvdDGjggLZLfG1pfWj5epsfGj_4WIk

  Unfortunately, the prognosis for high-grade gliomas is poor due to limited possibilities of curative treatment. […] Gliomas are well-known tumors at the molecular level. […] While our knowledge about the molecular biology of gliomas is rapidly expanding and is, to some extent, already assisting us in the design of tumor-tailored therapeutics, such as immunotherapy treatments, we are still struggling to develop efficient treatments. […] As a result, the overall survival rate of gliomas has not significantly increased in the last decades. […] Due to the absence of definitive surgical and medical treatments currently available, an early diagnosis coupled with an accurate tumor classification is crucial to select a personalized treatment. […] Therefore, the identification of molecular biomarkers is unquestionably essential and urgent for an accurate prognosis and development of critical therapeutic targets in gliomas.

• #138 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  Gliomas comprise the most frequent primary central nervous system (CNS) tumors, characterized by remarkable genetic and epigenetic heterogeneity, difficulty in monitoring, and increased relapse and mortality rates. […] Tissue biopsy is an established method of tumor cell collection and analysis that enables diagnosis, classification of different tumor types, and prediction of prognosis upon confirmation of tumor’s location for surgical removal. […] However, it is an invasive and often challenging procedure that cannot be used for frequent patient screening, detection of mutations, disease monitoring, or resistance to therapy. […] To this end, the minimally invasive procedure of liquid biopsy has emerged, allowing effortless tumor sampling and enabling continuous monitoring. […] It is considered a novel preferable way to obtain faster data on potential tumor risk, personalized diagnosis, prognosis, and recurrence evaluation.

• #139 Diagnosing Glioma & Astrocytoma | NYU Langone Health

  https://nyulangone.org/conditions/glioma-astrocytoma/diagnosis

  A CT scan uses X-rays to create cross-sectional, three-dimensional images of the brain. […] Functional MRI, or fMRI, uses MRI imaging to measure the tiny metabolic changes that occur in an active part of the brain. […] In a perfusion MRI, a doctor can view the amount of blood flowing through different parts of the brain, as well as through a tumor. […] A PET scan detects tumor growth using a small amount of radioactive glucose, or sugar, which is injected into a vein. […] A stereotactic biopsy is a surgical procedure in which a doctor removes a small amount of brain tissue using a probe that is directed by a three-dimensional, computerized navigation system. […] Our neuropathologists perform precision molecular DNA testing, a sophisticated analysis of the DNA mutations in the tumor.

• #140 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  Gliomas are highly complex and metabolically active brain tumors associated with poor prognosis. […] In this study, we performed metabolite analyses of blood samples collected from healthy controls and future glioma patients, up to eight years before glioma diagnosis, and on the day of glioma surgery. […] We discovered that metabolites related to early glioma development were associated with an increased energy turnover, as highlighted by elevated levels of TCA-related metabolites such as fumarate, malate, lactate and pyruvate in pre-diagnostic cases. […] High amino acid turnover in glioma tumor tissue is currently utilized for PET imaging, diagnosis and delineation of tumor margins. […] By examining blood-based metabolic progression patterns towards disease onset, we demonstrate that this high amino acid turnover is also detectable in a simple blood sample.

• #141 Advances on Liquid Biopsy Analysis for Glioma Diagnosis

  https://www.mdpi.com/2227-9059/11/9/2371

  The purpose of this review is to describe the advances on liquid biopsy for glioma diagnosis and management, indicating several biomarkers that can be utilized to analyze tumor characteristics, such as cell-free DNA (cfDNA), cell-free RNA (cfRNA), circulating proteins, circulating tumor cells (CTCs), and exosomes. […] It further addresses the benefit of combining liquid biopsy with radiogenomics to facilitate early and accurate diagnoses, enable precise prognostic assessments, and facilitate real-time disease monitoring, aiming towards more optimal treatment decisions. […] In this review, we describe recent advances on liquid biopsy analysis for glioma patients, pointing towards the most promising biomarkers that can be used to explore tumor characteristics. […] The ability of a liquid biopsy to analyze tumor products that are found in body fluids has led to its increasing utilization in different types of tumors.

• #142 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #143 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #144 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #145 Blood based metabolic markers of glioma from pre-diagnosis to surgery | Scientific Reports

  https://www.nature.com/articles/s41598-024-71375-6

  These findings provide additional insight of metabolic alterations during glioma development and progression. […] Given the poor prognosis and limited treatment options, early detection of glioma development is important in order to treat patients at an earlier stage of the disease progression. […] Interestingly, markers of glioma development have been reported to appear several years before a patient is diagnosed with a brain tumor. […] These markers include altered metabolite levels in blood, which have been found in several studies. […] Recently, it was shown that glioma development can be detected in blood up to at least two years before diagnosis with a panel of 20 metabolites in a multicenter pan-European cohort. […] These findings highlight the possibility of an earlier detection of glioma, which could potentially lead to an improved prognosis and outcome for glioma patients.

• #146 New Blood Test Enables Minimally Invasive Glioma Diagnosis | Clinical Lab Products

  https://clpmag.com/diagnostic-technologies/molecular-diagnostics/new-blood-test-enables-minimally-invasive-glioma-diagnosis/

  Results from our plasma testing demonstrate an overall sensitivity of 75.0%, specificity 88.7%, positive predictive value 90.9%, and negative predictive value 70.1% compared to the tissue gold standard. […] Detection of the IDH1 mutation in blood means that these tumors can be diagnosed without a biopsy, and can be monitored overtime to track disease progression, response to treatment or recurrence using a simple blood sample. […] Importantly, the FDA recently approved a drug (vorasidenib) for this mutation in glioma this means that the test, once approved, can be used to stratify these patients for this treatment and can monitor disease course.

• #147 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  When evaluating a patient with a suspected glioma, it is crucial to consider a range of differential diagnoses to ensure accurate diagnosis and appropriate treatment. […] Several techniques have been used to increase the extent of resection of gliomas, including intraoperative MRI and fluorescein-guided resections. […] Postoperative radiation therapy aims to eliminate residual tumor cells, reduce recurrence risk, and prolong survival. […] The prognosis of patients with gliomas depends on several factors, as follows: Age of the patient, Comorbidities, Grade and location of the tumor, Presence of hydrocephalus, Response to adjuvant therapy, Extent of surgical resection. […] Patients with gliomas benefit from consultations with a multidisciplinary team of specialists to ensure comprehensive and personalized care. […] Deterrence and patient education are crucial components in managing gliomas, aiming to improve patient outcomes and quality of life.

• #148 Diffuse Midline Glioma: Diagnosis and Treatment – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/tumors/diffuse-midline-gliomas

  To get an accurate diagnosis, a piece of tumor tissue will be removed during surgery, if possible. A neuropathologist should then review the tumor tissue. […] Diffuse midline gliomas are all grade 4 (also written as grade IV). This means they are malignant (cancerous) and fast-growing. […] In adults, a diffuse midline glioma diagnosis cant be made by imaging alone, because the tumors look similar to glioblastomas and other high-grade brain cancers. […] Because it can be hard to tell them apart, molecular testing is required. Some diffuse midline gliomas have changes in histone-related genes. The most common gene is h3K27M. A neuropathologist should confirm the diagnosis. […] The first treatment for diffuse midline glioma is surgery, if possible. The goal of surgery is to obtain tissue to determine the tumor type and remove as much tumor as possible without causing more symptoms. […] A team of experts including neuro-oncologists, neuroradiologists, radiation oncologists, and neurosurgeons should review the tumor to determine the best treatment plan.

• #149 Glioma | Neuro-Oncology | UH Seidman Cancer Center | University Hospitals | Cleveland, OH | University Hospitals

  https://www.uhhospitals.org/services/cancer-services/neuro-oncology/diagnosis-and-treatments/gliomas

  Survival rates for gliomas vary according to the type of glioma, tumor grade and the patients age. […] Surgery may be used in both the diagnosis and treatment of gliomas. Surgical removal of the tumor helps reduce pressure on nearby parts of the brain. […] Radiation therapy involves the use of high-energy x-rays or other types of radiation to kill cancer cells or prevent them from growing. […] Chemotherapy uses drugs to stop the growth of cancer cells, either by killing the cells or preventing their division. […] Targeted therapy is an approach to treatment that utilizes drugs or other substances to identify and attack specific cancer cells. […] University Hospitals is an affiliate of Case Western Reserve University School of Medicine, a nationally recognized leader in clinical research. […] Our multidisciplinary group reviews and evaluates every case so that diagnosis and treatment decisions are based on the teams combined knowledge, insights and experience.

• #150 Glioma Diagnosis and Classification: Illuminating the Gold Standard | SpringerLink

  https://link.springer.com/chapter/10.1007/978-3-030-72084-1_1

  Accurate glioma classification is essential for optimal patient care, and requires integration of histological and immunohistochemical findings with molecular features, in the context of imaging and demographic information. […] This paper will introduce classic histologic features of gliomas in contrast to nonneoplastic brain parenchyma, describe the basic clinical algorithm used to classify infiltrating gliomas, and demonstrate how the classification is reflected in the diagnostic reporting structure. […] Key molecular features include IDH mutational status and 1p/19q codeletion. […] In addition, molecular changes may indicate poor prognosis despite lower grade histology, such as findings consistent with two grade IV infiltrating gliomas: molecular glioblastoma and diffuse midline gliomas. […] Detailed molecular characterization aids in optimization of treatment with the goal of improved patient outcomes.

• #151 Gliomas – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK441874/

  When evaluating a patient with a suspected glioma, it is crucial to consider a range of differential diagnoses to ensure accurate diagnosis and appropriate treatment. […] Several techniques have been used to increase the extent of resection of gliomas, including intraoperative MRI and fluorescein-guided resections. […] Postoperative radiation therapy aims to eliminate residual tumor cells, reduce recurrence risk, and prolong survival. […] The prognosis of patients with gliomas depends on several factors, as follows: Age of the patient, Comorbidities, Grade and location of the tumor, Presence of hydrocephalus, Response to adjuvant therapy, Extent of surgical resection. […] Patients with gliomas benefit from consultations with a multidisciplinary team of specialists to ensure comprehensive and personalized care. […] Deterrence and patient education are crucial components in managing gliomas, aiming to improve patient outcomes and quality of life.

Zobacz więcej